Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
THE MAGAZINE FOR NEW ZEALAND’S OPHTHALMIC COMMUNITY<br />
PO BOX 106 954, AUCKLAND CITY 1143<br />
Email: info@nzoptics.co.nz Website: www.nzoptics.co.nz<br />
JUNE <strong>2016</strong><br />
LEAVE A LEGACY OF<br />
EXCELLENT OUTCOMES<br />
FOR PATIENTS WITH<br />
PRESBYOPIA.<br />
Start with ME.<br />
TECNIS Symfony and TECNIS are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates.<br />
Australia: Abbott Medical Optics, 299 Lane Cove Road, Macquarie Park, NSW 2113, Australia. New Zealand: Abbott Medical Optics (AMO Australia Pty Ltd) PO Box 401, Shortland Street, Auckland, 1140.<br />
©<strong>2016</strong> Abbott Medical Optics Inc. www.AbbottMedicalOptics.com PP<strong>2016</strong>CT0415
IT’S TIME TO PLAY...<br />
OFFER<br />
EXTENDED<br />
TO END<br />
OF JUNE!<br />
$..‘000’S ON OFFER FOR EVERY REFERRAL<br />
OR… REFER YOURSELF AND STILL TAKE HOME THE $$<br />
With a market shortage of optometrists in both Australia and New Zealand, alongside a goal<br />
of further growth from Specsavers franchise partners in <strong>2016</strong>, we’re taking a new<br />
approach to boosting our optometry team – and everyone can benefit.<br />
Until the end of <strong>Jun</strong>e, every optometrist you refer to our recruitment<br />
teams – who subsequently joins us as a locum, as a partner or in an employed role<br />
- will earn a ‘Refer a Friend’ payment. Depending on the location<br />
and role taken up, payments you are eligible for range from $1000 to $50,000!<br />
And here’s a tip – if you’re really up for it and refer yourself, you’ll still be<br />
entitled to claim your referral payment…<br />
To find out more and to explore the Terms and Conditions associated with this<br />
industry-wide offer, contact Carly Parkinson on 0800 717 350 or<br />
carly.parkinson@specsavers.com – or visit spectrum-blog.com.<br />
Retail<br />
Employer<br />
of the Year<br />
2015<br />
Franchise<br />
Innovation<br />
Award<br />
2015<br />
NZ Franchise<br />
System of<br />
the Year<br />
2014<br />
Retail<br />
Innovator<br />
of the Year<br />
2014<br />
Multichannel<br />
Retailer<br />
of the Year<br />
2014<br />
Roy Morgan<br />
Research<br />
No. 1 for eye tests<br />
2014<br />
FCA International<br />
Franchisor<br />
of the Year<br />
2014<br />
FCA Social<br />
Responsibility<br />
Award<br />
2014<br />
FCA Established<br />
Franchisor<br />
of the Year<br />
2013<br />
FCA Excellence<br />
in Marketing<br />
Award Winner<br />
2013<br />
Australian<br />
Retailer<br />
of the Year<br />
2013<br />
2 NEW ZEALAND OPTICS <strong>Jun</strong>e <strong>2016</strong>
From frustrated<br />
ophthalmologist to entrepreneur<br />
A month<br />
of firsts<br />
After becoming increasingly exasperated with the inefficient way the system dealt with<br />
cataract surgery referrals, Dr James McKelvie decided to do something about it.<br />
BY JAI BREITNAUER<br />
Around 30,000 people have cataract surgery<br />
in New Zealand each year, says Dr James<br />
McKelvie, a corneal fellow at the University<br />
of Auckland and Auckland District Health Board.<br />
“It’s the most frequently performed surgical<br />
procedure in New Zealand by far, and the public<br />
health system in New Zealand is likely to struggle<br />
with the increasing demand for cataract surgery in<br />
the near future.”<br />
The way the system works right now, and has<br />
done for some time, is that a GP or community<br />
optometrist will identify a possible need for surgery,<br />
write a referral – often by hand – and post it. The<br />
patient has to wait for the letter to be assessed by<br />
the administration staff and triaged before they can<br />
be booked into an appointment with a specialist to<br />
find out if they are eligible for surgery. The patient is<br />
then placed on the surgical waiting list, and then it<br />
may take up to another four months until they have<br />
their surgery.<br />
“From a patient perspective the current system,<br />
with the long waiting time and uncertainty around<br />
surgery, is not ideal,” says Dr McKelvie. “Cataracts<br />
are normally identified at the time of an event; like<br />
failing an eye sight test for a drivers licence. This<br />
means the situation is both urgent and distressing<br />
for the patient.”<br />
On top of that, DHBs are missing out on the<br />
opportunity to collect vital data that could help<br />
identify the burden of cataract in the community, he<br />
says. This data would enable the health community<br />
to plan ahead and ensure surgical intervention<br />
rates and access to surgery between DHBs, ethnic<br />
subgroups and all geographic locations remains<br />
consistent across New Zealand.<br />
To tackle the problem, Dr McKelvie began<br />
designing an electronic, real-time referral system in<br />
his spare time that could reduce wait times and give<br />
patients immediate information, as well as record<br />
data in a uniform and useful way.<br />
“It’s a web-based app that a GP or optometrist can<br />
use on a computer, phone or tablet,” he explains.<br />
“While they’re still with the patient, they can use the<br />
app to send a referral to the hospital.”<br />
This referral will not only reach the relevant team<br />
in the hospital quicker, it will include significantly<br />
more, relevant, clinical data that can be used at the<br />
pre-surgical appointment.<br />
The app also processes the application instantly<br />
and assesses whether the patient meets the<br />
criteria for surgery, says Dr McKelvie. “This means<br />
that within a few minutes the patient can leave<br />
their GP’s or optometrist’s office either with a<br />
plan for community-based care or a pre-surgery<br />
appointment with an ophthalmologist.” (Fig. 1)<br />
It also means the DHB using the system can<br />
capture useful information about both the patients<br />
referred and those in community care that are subthreshold,<br />
to allow better predictions to be made<br />
about the volume of people that are likely to require<br />
surgery in the near future.<br />
Dr McKelvie’s app doesn’t stop there, however. As<br />
well as being a system for electronic referral, the<br />
app can complete a risk assessment and a real-time<br />
audit of cataract surgery to help the surgeons.<br />
“Phase two of the project will seek to digitise the<br />
information we collect in a pre-surgery appointment<br />
and provide a risk analysis,” he explains.<br />
Currently, a clinical exam before surgery requires<br />
a variety of different tests and measurements to<br />
be taken, typically generating 20 to 30 pages of<br />
hand-written notes, forms and calculations for each<br />
operation.<br />
“Ophthalmologists are notorious for their<br />
excellent attention to detail and careful assessment<br />
and documentation of a surgical plan” says Dr<br />
McKelvie. “This close attention to detail is partly<br />
why the vast majority of patients achieve excellent<br />
outcomes following cataract surgery. However, there<br />
is no doubt this system can be improved upon using<br />
the benefits of cloud-based computing to improve<br />
efficiency and add another layer of error checking.”<br />
Dr McKelvie’s system will introduce a paperless,<br />
digitised trail of standardised information relating<br />
to each patient, including a comprehensive, concise,<br />
one-page summary of all relevant information<br />
required in the operating theatre. As part of this<br />
summary each patient will have an evidence-based<br />
Dr James McKelvie is working on<br />
a real-time referral system<br />
risk assessment that<br />
uses a number of<br />
variables to predict the<br />
probability of a major<br />
complication during<br />
surgery. High risk cases<br />
will be highlighted as<br />
less suitable for junior<br />
trainee surgeons to<br />
reduce the risk of<br />
complications and<br />
improve outcomes for<br />
patients. Other features<br />
include a customised<br />
consent form, electronic operation note and several<br />
additional features that will improve efficiency and<br />
patient safety in the operating theatre.<br />
“The third stage of the project is a real-time<br />
audit of surgical results,” says Dr McKelvie. “At the<br />
moment, audits are time consuming and very labour<br />
intensive, so they’re typically performed sparingly<br />
on selected cohorts of patients. This system will<br />
allow all patient data to become part of an audit,<br />
effortlessly conducted in real time.”<br />
With an up-to-date, confidential and secure audit<br />
of personal surgical data at their fingertips, on<br />
their phone or computer, surgeons will be able to<br />
access vital feedback about their surgical outcomes<br />
and have the ability to compare their results with<br />
those of an (anonymised) pool of their peers. This<br />
will provide information about different surgical<br />
techniques, complications and visual outcomes and<br />
can provide customised data that will be of interest<br />
to surgeons, such as personalised A-constants,<br />
surgically-induced astigmatism and more. “This<br />
information may be used to refine surgical<br />
techniques, calculations and further improve visual<br />
outcomes for patients,” says Dr McKelvie.<br />
Since presenting his ideas at the Health<br />
Informatics New Zealand Conference in Christchurch<br />
in October, where he won the Clinician’s Challenge:<br />
Fig 1. Dr James McKelvie’s real-time referral ssystem will speed up the process from weeks to minutes<br />
CURRENT SYSTEM<br />
Community optom<br />
identifies a need for<br />
referal<br />
A hand written referal is posted<br />
5-10 DAYS<br />
Letters are sorted assessed and triaged<br />
10-14 DAYS<br />
Patient receives a response<br />
3-4 WEEKS<br />
New Ideas category, Dr McKelvie has been<br />
congratulated by Health Minister Jonathan Coleman<br />
and received a number of expressions of interest<br />
from parties across New Zealand.<br />
He is currently working on perfecting the<br />
prototype, with the Waikato DHB lined up to trial<br />
the system later this year. Auckland DHB have also<br />
expressed interest in trialling the system in the<br />
near future.<br />
“I’ve had some fantastic feedback. The<br />
possibilities for this system across health in<br />
general are endless,” says Dr McKelvie.<br />
“I didn’t set out to be a businessman or an<br />
entrepreneur, and I’m no IT expert, but I’m<br />
interested in new ideas and wanted to see the<br />
best outcome for patients and ophthalmologists.<br />
Once people heard about the project it took on a<br />
life of its own.”<br />
Dr McKelvie admits there are still challenges<br />
ahead, but says it is exciting to see the potential of<br />
a system like this. “The ophthalmologists that have<br />
seen what this can do for them are very enthusiastic<br />
to start using it as soon as possible. Naturally<br />
change is often difficult, but the aim of this system<br />
is to make cataract surgery better, faster and<br />
safer for everyone, while making better use of our<br />
resources to address the increasing demand for<br />
cataract surgery in the future.”<br />
It’s fair to say this is a critical time in the<br />
healthcare industry, with medicine becoming<br />
increasingly more digitised, says Dr McKelvie,<br />
adding if he hadn’t come up with the idea, nodoubt<br />
someone else would have.<br />
“There are not enough doctors or dollars to<br />
address the critical mass of patients we are heading<br />
toward, our only choice is to get smarter about<br />
the way we do things. Cataract surgery is the most<br />
common surgical procedure in New Zealand – if<br />
we can make the change for cataract surgery,<br />
chances are we could apply this to other areas of<br />
ophthalmology and surgery also.” ▀<br />
<br />
<br />
<br />
APPOINTMENT REQUEST<br />
Date: 18-May <strong>2016</strong><br />
Dear Joe Brown<br />
Ulpa eum int vendio to dolla que praeptumquasDandi<br />
qui officiusam, con porerion prorem faceraernat option<br />
nos aut vellecto temquas pellestias aut et vendit quae.<br />
Ehenem et, sinulla boremped exerias velest, quuntint,<br />
temporeium re accum sum quam, tem apis simin rest<br />
labo. Ullaut optate ex eum arum dolorem. Itassi andi quo<br />
totae sed ma none qui odi blab.<br />
Regards<br />
Dr Lesley Springall<br />
EDITORIAL<br />
Welcome to your <strong>Jun</strong>e issue of<br />
NZ Optics – my first full issue at the<br />
helm. Thus far, Lesley has very kindly<br />
steered me through the early stages of taking<br />
on the editor’s role, and I’m excited to have<br />
now been set free (relatively speaking!) on this<br />
wonderful title.<br />
This issue contains several other firsts, such<br />
as the CentraSight surgery performed on an<br />
MD patient in Tauranga, the first of its kind in<br />
the Southern Hemisphere (p4) and news about<br />
New Zealand’s upcoming hosting of the APAO<br />
conference – the first time an event of this size<br />
has made it to Aotearoa (p4).<br />
Another first in the events calendar was the<br />
Ocular Therapeutics one-day conference, which<br />
we cover in detail inside (p8-9). We talk to Dr<br />
James McKelvie about the ground breaking,<br />
real-time referral and audit software he will<br />
be trialling later this year (this page), and we<br />
celebrate Associate Professor Dr Dr Bruce<br />
Hadden and the Optometry School class of<br />
2015, who graduated on 11 May (p17 and p19).<br />
I hope you enjoy the magazine, and whether<br />
you want to congratulate us or berate us, rest<br />
assured our virtual doors are always open. We’d<br />
love to hear your feedback and suggestions<br />
via email, editor@nzoptics.co.nz – and who<br />
knows, you might even find your kind words or<br />
constructive criticism in print! ▀<br />
Jai Breitnauer, editor, NZ Optics<br />
NEW CLOUD- BASED SYSTEM<br />
Community optom<br />
identifies a need for<br />
referal<br />
They complete an online referal while<br />
patient is present<br />
2 MINUTES<br />
They receive an instant response<br />
and pre-surgery appointment if<br />
necessary<br />
30 SECONDS<br />
<br />
<br />
APPOINTMENT REQUEST<br />
<strong>Jun</strong>e <strong>2016</strong><br />
NEW ZEALAND OPTICS<br />
3
News<br />
in brief<br />
EYE TESTS FOR DRIVER LICENCES UNDER REVIEW<br />
The Ministry of Transport is considering allowing drivers to renew<br />
their driver licences online without the need for an eye test. People<br />
will still have to get their eyes tested when they first get a licence<br />
and after age 75, but only make a declaration about the state<br />
of their eyesight when renewing their licence online. The Driver<br />
Licensing system is under review as part of the Government’s<br />
commitment to achieve a more efficient transport regulatory<br />
system. A discussion paper was released on 19 April <strong>2016</strong> and<br />
submissions are due to close on 2 <strong>Jun</strong>e.<br />
AVENOVA PUBLISHES CLINICAL DATA<br />
NovaBay published clinical data at the ARVO meeting in Seattle<br />
demonstrating its lid and lash hygiene product, Avenova, reduced<br />
the bacterial load on the ocular surface by more than 90% in 20<br />
minutes without affecting the diversity of bacteria remaining. This<br />
made Avenova the only commercial clinical product validated in<br />
a multicentre study to substantially reduce the bacteria that can<br />
cause blepharitis, said Glenn Moro, NovaBay’s vice president, sales<br />
and marketing.<br />
ARVO NEWS<br />
In other news from ARVO <strong>2016</strong>, results from a series of pre-clinical<br />
studies provided proof-of-principle that gene targeting using<br />
CRISPR-Cas9 genome-editing technology can prevent or treat<br />
glaucoma associated with mutations in the myocilin (MYOC) gene.<br />
The research was led by Professor Val Sheffield from University of<br />
Iowa’s Carver College of Medicine.<br />
Professor Douglas Jabs, chair of the Department of Ophthalmology<br />
and Professor of Medicine at the Mount Sinai School of Medicine<br />
in New York City, said modern combination antiretroviral therapy<br />
(cART) has transformed the AIDS epidemic and the management<br />
of cytomegalovirus (CMV) retinitis. Information presented by<br />
Professor Jabs at ARVO demonstrated interactions between CMV<br />
and HIV and the importance of the immune response in controlling<br />
CMV disease. For more on ARVO, see page 19.<br />
RACS SEEKS TO ELIMINATE DISCRIMINATION<br />
In May, the Royal Australasian College of Surgeons (RACS) launched<br />
Let’s Operate with Respect, a call to action for the 7,000 surgeons<br />
and 1,300 trainees in Australia and New Zealand to put an end to<br />
discrimination, bullying and sexual harassment in surgery. “We<br />
know these problems are common throughout the health sector,<br />
but it’s up to us to improve things in surgery,” said RACS President,<br />
Professor David Watters OBE.<br />
The Let’s Operate With Respect campaign results from the<br />
recommendations of an Expert Advisory Group established last<br />
March in response to complaints. It aims to get surgeons talking<br />
about these problems and affect a culture change in the profession.<br />
ALCON’S DRY EYE ACADEMY<br />
Launched in 2013, Alcon’s Dry Eye Academy is led by<br />
ophthalmologists and optometrists with expertise in identifying<br />
and treating dry eye. The next New Zealand workshop will be held<br />
in Auckland on Sunday 31 July.<br />
LIQUID CLS SHARPEN IMAGES EVEN AT NIGHT<br />
New ‘artificial eye’ liquid contact lenses have been developed by<br />
Professor Hongrui Jiang from Wisconsin University in the US. The<br />
liquid contact lenses give perfect vision at any distance, even as<br />
conditions change and it gets darker, and automatically focus in<br />
less than a blink of an eye, using tiny, solar-powered computers,<br />
said Professor Jiang in a report on his discovery published in<br />
Proceedings of the National Academy of Sciences.<br />
SONY TOPS SAMSUNG’S PATENT<br />
Sony has filed a patent application for a smart contact lens that<br />
can take photos and record videos at the blink of an eye and play<br />
back the captured images for the user. The move comes hot on the<br />
heels of Samsung’s patent, which was filed in April, for a contact<br />
lens with a tiny camera that can be controlled by blinking. Sony’s<br />
lens, however, also includes a storage medium negating the need<br />
for an external storage device, while Samsung’s requires captured<br />
images to be sent to another device, such as a smartphone.<br />
ACADEMIC MOOD LIGHTING<br />
There is a science behind lighting that nightclubs and retailers<br />
understand and have invested in for many years, but now, thanks<br />
to new research, the “right” lighting for academic achievement may<br />
make its way into schools. Researchers in a South Korean study,<br />
published in Optics Express at the end of April, found that lighting<br />
can be optimised for various activities from test-taking to reading.<br />
They characterised lighting by measuring different, correlatedcolour<br />
temperatures from “warm” to “cool” using the Kelvin scale<br />
and found different types had a profound effect on our physical and<br />
mental condition. ▀<br />
Telescopic treatment for AMD<br />
A<br />
new<br />
treatment programme for<br />
advanced macular degeneration<br />
(MD), called CentraSight, has finally<br />
made its way to New Zealand. The surgery,<br />
which involves inserting a tiny telescope<br />
into the eye of the patient in order to<br />
offer more visual acuity, had only been<br />
performed on a few hundred patients in<br />
the USA and UK until now. Consultant<br />
ophthalmologist Dr Mike O’Rourke of<br />
Tauranga Eye Specialists successfully<br />
performed the first operation of its kind in<br />
the Southern Hemisphere in February this<br />
year. The patient, 77-year-old Alisa Shaw<br />
from Whakatane, is recovering well.<br />
“The first study on this method was<br />
initiated in 2002 in the USA and the<br />
treatment earned FDA approval in 2008,”<br />
says Dr O’Rourke. “It was introduced in the<br />
UK three years ago. The surgery involves<br />
making a large incision around the limbus<br />
for 180 degrees to insert a 4.4mm glass<br />
telescope into the eye.”<br />
There is nothing special about the<br />
telescope itself, as optically it is a Galilean<br />
telescope, just miniaturised. It offers an<br />
almost 300% increase in the size of the<br />
image in one eye, making it easier for<br />
patients to see around the black spot that<br />
forms in their central vision.<br />
“Careful patient selection is key to<br />
the success of this surgery,” explains<br />
Dr O’Rourke. “The eyes will never work<br />
together again as the eye with the implant<br />
will be used for central vision, while the<br />
other eye will be relied upon for peripheral<br />
vision.”<br />
The pre-surgical assessment actually<br />
includes a simulation of the telescope to<br />
make sure patients can cope and the surgery<br />
will be beneficial. There are a number of<br />
other factors affecting patient selection<br />
also, says Dr O’Rourke.<br />
“Their bilateral MD needs to be stable,<br />
with no other health issues like diabetes or<br />
problems with the cornea. They need to be<br />
off any further macula treatment and be<br />
6/24 or worse in their best eye.”<br />
Then there’s the cost. The lens itself, handmade<br />
in Israel, costs $19,500 and then you<br />
need to account for the surgery and rehab<br />
An artist’s impression of the implant in the eye<br />
The telescopic implant is just 4.4mm<br />
costs. “It all adds up,” admits Dr O’Rourke,<br />
who expects to perform around four<br />
surgeries of this nature a year. “You won’t<br />
get much change from $30,000”.<br />
Another factor is there are only two New<br />
Zealand optometrists, Lynley Smith in<br />
Tauranga and Rodney Stedall in Hamilton,<br />
qualified to assess and recommend patients<br />
for surgery and to guide them through<br />
recovery, so ability to travel is important. A<br />
third optometrist may be travelling to the<br />
UK for training in the near future, adds Dr<br />
O’Rourke, but for patients like Alisa Shaw,<br />
whose sight had deteriorated to the point<br />
where she was unable to function on a daily<br />
basis, the CentraSight programme offers<br />
a new quality of life where patients had<br />
previously been told nothing could be done. ▀<br />
APAO coming to Auckland<br />
Auckland’s new, but as yet unbuilt,<br />
international conference centre<br />
is booked as the venue for one<br />
of the largest, if not the largest, medical<br />
conferences New Zealand has ever held when<br />
New Zealand plays host to the Asia-Pacific<br />
Academy of Ophthalmology (APAO) annual<br />
Congress in March 2020.<br />
Professor Charles McGhee, head of the<br />
Department of Ophthalmology at the<br />
University of Auckland and newly-made<br />
President Elect for APAO, will take on the twoyear<br />
APAO president term in 2019 and thus<br />
will be the convenor of the 2020 Congress.<br />
“This is a really big deal for New Zealand.<br />
We expect about 3,500 to 4,000 people and,<br />
allowing for a large industry subscription,<br />
we expect we may get as many as 4,200. It<br />
will bring people and exhibitors together<br />
from all over Asia and the Pacific. It’s the<br />
biggest grouping of (ophthalmological)<br />
societies there is.”<br />
Professor McGhee says just because he<br />
was made president elect at this year’s<br />
APAO Congress in Taipei, didn’t mean New<br />
Zealand would automatically host the 2020<br />
conference as Congress’s can be held in<br />
neighbouring countries. But given Australia<br />
was host in 2011 (ably helped by Professor<br />
McGhee who was then APAO scientific chair)<br />
it fell to New Zealand for 2020.<br />
APAO’s four-day congress attracts several<br />
hundred highly-experienced speakers from<br />
all over world, he says. “We will also run<br />
a number of instructor courses so junior<br />
surgeons can upskill and more experienced<br />
surgeons can re-skill.<br />
“A major international conference allows<br />
you to network across many different<br />
platforms, exchange ideas from many<br />
different societies and economic groups.<br />
Different ethnicities have different diseases so<br />
what is state-of-the-art in Australia and New<br />
Zealand might be quite different to what is in<br />
China or India.”<br />
Though the event is about building<br />
relationships with peers overseas and<br />
education, Professor McGhee says he expects<br />
the exhibition side to be the biggest ever held<br />
in New Zealand as well, as it’s one of the few<br />
times the industry side of the profession can<br />
expose their products and ideas to more than<br />
4,000 ophthalmologists in one place.<br />
The 31 st APAO in Taipei in March this year<br />
was very well attended and very exciting,<br />
he says, with a good showing from the New<br />
Zealand ophthalmological side. Highlights<br />
included a memorandum of understanding<br />
between APAO and Sight for All, a non-profit<br />
Australian organisation, that enables the<br />
organisations to work together on the first<br />
APAO Gateway Project in Laos.<br />
The APAO Gateway Projects were conceived<br />
as a way for wealthier nations to help<br />
those in need. They encompass all the main<br />
charitable and non-profit groups throughout<br />
the Asia-Pacific region, and the relevant<br />
government health departments, to reduce<br />
avoidable blindness and visual impairment in<br />
Professor Charles McGhee<br />
Dr Mike O’Rouke has brought the<br />
CentraSight programme to NZ<br />
a region of need.<br />
APAO was founded in 1960 by Budapestborn,<br />
but Hawaiian-based ophthalmologist<br />
Dr William John Holmes, with the<br />
principal objective of fostering closer<br />
relationships among ophthalmologists and<br />
ophthalmological societies in the Asia-<br />
Pacific region in order to combat blindness.<br />
Other objectives are to encourage the free<br />
exchange of ophthalmic knowledge and the<br />
advancement of the standard of eye care. ▀<br />
www.nzoptics.co.nz | PO Box 106954, Auckland 1143 | New Zealand<br />
For general enquiries, please email info@nzoptics.co.nz<br />
For editorial and classifieds, please contact Jai Breitnauer, editor, on 022 424 9322 or editor@nzoptics.co.nz.<br />
For advertising, marketing, the OIG and everything else, please contact Lesley Springall, publisher, on 027 445 3543 or lesley@<br />
nzoptics.co.nz.<br />
To submit artwork, or to query a graphic, please email lesley@nzoptics.co.nz.<br />
NZ Optics magazine is the industry publication for New Zealand’s ophthalmic community. It is published monthly, 11 times<br />
a year, by New Zealand Optics 2015 Ltd. Copyright is held by NZ Optics 2015 Ltd. As well as the magazine and the website,<br />
NZ Optics publishes the annual New Zealand Optical Information Guide (OIG), a comprehensive listing guide that profiles the<br />
products and services of the industry. NZ Optics is an independent publication and has no affiliation with any organisations. The<br />
views expressed in this publication are not necessarily those of NZ Optics (2015) Ltd.<br />
4 NEW ZEALAND OPTICS <strong>Jun</strong>e <strong>2016</strong>
New optometry collective<br />
launches in Australia<br />
Call to action<br />
for children<br />
George & Matilda Eyecare (G&M), a new<br />
optometry group headed by Luxottica’s<br />
former Asia-Pacific CEO Chris Beer, launched<br />
in Australia last month and is on the hunt for<br />
Australian optometry businesses to join the brand.<br />
According to the company’s website, G&M is<br />
an Australian-owned and operated optometry<br />
collective. “We offer leading optometrists a unique<br />
partnership model that’s unlike any other franchise<br />
or buying group in the optical industry.”<br />
The branding and advertising for G&M is being<br />
handled by Saatchi & Saatchi, which worked with<br />
Beer when he worked with OPSM on the successful<br />
Penny the Pirate children’s screening book and app<br />
campaign.<br />
In an announcement to the Australian marketing<br />
press, Beer commented: “George & Matilda is<br />
all about providing customers with stylish, fresh<br />
products in an approachable and familiar way. We<br />
want people to get more out of their optometry<br />
experience and Saatchi & Saatchi’s strategic and<br />
creative approach to this ambition will help us<br />
differentiate immediately.”<br />
Michael Rebelo, chairman and CEO of Saatchi<br />
& Saatchi Australia said it wasn’t often the<br />
company was given the chance to build a brand<br />
from a blank sheet of paper. “This has been a<br />
unique opportunity for our team to leverage<br />
our experience in this industry and apply it to a<br />
disruptive start-up business.”<br />
The name George & Matilda was chosen to reflect<br />
Australia and the vision of the brand with George<br />
representing the first high street in Australia and<br />
Matilda echoing one of the nation’s favourite songs.<br />
The new collective has already signed up the<br />
11 practices of Port Macquarie-based Hanks<br />
Optometrists and Peter Hewett Optometry in<br />
Mosman, Sydney.<br />
Beer did not return NZ Optics’ calls by press time.<br />
• Another new chain also launched in Australia<br />
last month, Better Eyecare. The new group is 60%<br />
owned by optometrist Paul Sheehan, now CEO of<br />
Better Eyecare, with the remaining 40% held by<br />
CFO Anthony Anderson and COO Michael Tanzer.<br />
Speaking to Insight magazine, Sheehan said<br />
Better Eyecare is an Australian-owned and<br />
operated company that has identified a prime<br />
opportunity in the Australian market to aggregate<br />
profitable practices into a new group that will<br />
compete with existing corporate groups. ▀<br />
The Brien Holden Institute, a global nonprofit<br />
scientific research and education<br />
organisation, has teamed up with Vision<br />
for Life, an Essilor social impact initiative, to<br />
tackle the growing problem of childhood myopia.<br />
Announced in New York on 12 April, their new,<br />
joint campaign, Our Children’s Vision, aims to<br />
screen 50 million children worldwide by 2020.<br />
Recent research from the Brien Holden Institute<br />
indicates that by 2050, 4.76 billion people (half<br />
the current global population) will suffer from<br />
myopia, with the majority of them needing<br />
glasses.<br />
Our Children’s Vision aims to encourage<br />
countries to act now to tackle the increasing<br />
impact poor eyesight has on educational<br />
outcomes and social development.<br />
“[Children with uncorrected vision] can’t play<br />
outside safely, so they struggle to make friends.<br />
They can’t see the blackboard, so they struggle<br />
to learn. They are hindered in every aspect of<br />
their life and it doesn’t stop at childhood,” said<br />
Jayanth Bhuvaraghan, chairman of Vision For<br />
Our childern’s vision graphic<br />
Life and chief corporate mission officer at Essilor<br />
International.<br />
Yet many children, particularly those in some of<br />
the poorest communities, don’t have access to eye<br />
care. This issue has already been highlighted in<br />
New Zealand by Essilor, who has implemented its<br />
own Essilor Vision Foundation initiative, screening<br />
children in decile 1 and 2 schools (NZ Optics, May<br />
<strong>2016</strong>, p4). But the Our Children’s Vision campaign<br />
takes this concern to the next, global level of action.<br />
“We are potentially facing the biggest public<br />
health challenge of our generation,” said<br />
Professor Kovin Naidoo, CEO, Brien Holden Vision<br />
Institute and campaign director for Our Children’s<br />
Vision. “This trend can be slowed down through<br />
preventative or corrective care, but only if a child<br />
is reached while their eyes are still developing. An<br />
effective eye health programme in schools would<br />
have an unprecedented impact. Our Children’s<br />
Vision is a global campaign designed to make this<br />
impact a reality. We need to act now.”<br />
For more information, visit<br />
www.ourchildrensvision.org. ▀<br />
Education Series <strong>2016</strong><br />
Seminars<br />
are FREE!<br />
NEXT SEMINAR<br />
Tuesday 16th August<br />
6.30pm - 8.45pm<br />
Theme:<br />
Diagnostics and<br />
Therapeutics in<br />
Everyday Practice<br />
Venue:<br />
Ellerslie Event Centre<br />
Racecourse, 80 Ascot Ave<br />
Ellerslie, Auckland<br />
Eye Institute’s Education Series continues to offer an opportunity for the Optometry Profession to gain exposure<br />
to the latest advances in therapeutics, shared-care management and surgical advances in New Zealand.<br />
You are invited to join us at our August Seminar and November Conference for the <strong>2016</strong> year.<br />
Optometry Conference<br />
Sunday 6th November<br />
8am - 5pm<br />
Waipuna Hotel & Conference Centre,<br />
58 Waipuna Road, Mt Wellington, Auckland<br />
PLUS 1/2 day workshops<br />
Saturday PM 5th November<br />
REGISTER ONLINE:<br />
www.eyeinstitute.co.nz/optometry<br />
Dispensing Optician Conference<br />
Sunday 6th November<br />
8am - 5pm<br />
Waipuna Hotel & Conference Centre,<br />
58 Waipuna Road, Mt Wellington, Auckland<br />
August Seminar generously<br />
sponsored by<br />
Registration:<br />
5.45pm - 6.30pm<br />
Light Meal & Beverages<br />
provided<br />
BOOK NOW!<br />
for your <strong>2016</strong> CPD Credits<br />
(including Therapeutics)<br />
Or register by contacting...<br />
Tracy Richmond<br />
Ph 09 522 2125 | Fax 09 522 5770<br />
conference@eyeinstitute.co.nz<br />
<strong>Jun</strong>e <strong>2016</strong><br />
NEW ZEALAND OPTICS<br />
5
Eyeing the power of algae<br />
New Zealand’s ophthalmic<br />
community is being targeted for<br />
direct sales of a home-grown<br />
“super-antioxidant” product<br />
harvested from algae.<br />
Celebrating<br />
excellence<br />
BY LESLEY SPRINGALL<br />
Kiwi supplement company Supreme<br />
Biotechnologies’ move into the world of eye<br />
health was completely serendipitous.<br />
Founder and chief executive Tony Dowd was<br />
seeking further investment for the company’s<br />
AstaSupreme products, when one London-based<br />
potential investor, who’d been using the product<br />
for a couple of months, asked if astaxanthin was<br />
any good for eyes.<br />
Astaxanthin (pronounced asta-zan-thin),<br />
a carotenoid found in algae and responsible<br />
for the red colour in salmon and shellfish, is a<br />
powerful antioxidant and the key ingredient in<br />
AstaSupreme products. The investor was a City<br />
trader who spent long hours in front of a screen<br />
and normally went home with very sore eyes.<br />
But, since taking AstaSupreme, said he’d noticed<br />
a remarkable improvement in how his eyes felt at<br />
the end of a long day.<br />
The observation led to some serious research by<br />
Dowd, key to which was a 1994 study by Dr Mark<br />
Tso of the University of Illinois, who discovered<br />
(or confirmed, as many claim to have spotted the<br />
benefits of astaxanthin for eyes over the years) that<br />
astaxanthin can help halt the progression of and<br />
prevent macular degeneration as well as protect<br />
our eyes against photic injury, ischemic diseases<br />
and inflammatory diseases.<br />
Further research led to Supreme Biotechnologies<br />
developing AstaSupreme Advanced Eye Care, with<br />
astaxanthin and the AREDS2 (see box) verified<br />
carotenoids, lutein and zeaxanthin, plus other<br />
products known to be important to eye health,<br />
including zinc and saffron.<br />
The product has been available through<br />
pharmacists and online for nearly 18 months<br />
now and qualitative studies by the company,<br />
sales growth and repeat purchase data is proof of<br />
how good it is, claims Dowd, who says he’s had<br />
to reduce his lens prescription twice in the last<br />
three years since taking AstaSupreme products.<br />
Sales have been so good in New Zealand—<br />
where Supreme Biotechnologies rolls out all its<br />
products first before taking them to the world—<br />
AstaSupreme Advanced Eye Care is now the<br />
company’s second highest selling product.<br />
Given the positive feedback, Dowd is now keen to<br />
introduce the product to New Zealand’s ophthalmic<br />
community, so they can sell it direct to consumers,<br />
with a hefty margin for themselves, of course, he<br />
laughs. He admits some education is required,<br />
however, as most of the profession is familiar with<br />
AREDS2 formulations, but not so familiar with the<br />
benefits of astaxanthin or saffron (despite saffron<br />
being used for eye remedies for many years).<br />
Dowd has considered, and is still considering,<br />
developing a specific product just for eye health<br />
Oculo launches<br />
Dr Kate Taylor<br />
and her team<br />
at Oculo, based<br />
in Melbourne,<br />
have successfully<br />
gained approval<br />
from the National<br />
Health Information<br />
Technology Board<br />
for their cloudbased<br />
clinical<br />
communication<br />
software and will<br />
Dr Kate Taylor, head of Oculo<br />
be rolling it out in<br />
New Zealand from<br />
the start of <strong>Jun</strong>e.<br />
“It’s a really exciting time for us,” said Dr Taylor,<br />
who began testing the platform in July 2015. “It’s<br />
wonderful to see a good idea flourishing.”<br />
In October, NZ Optics first reported on Oculo,<br />
whose software was born from work at the Centre<br />
for Eye Research Australia (CERA) and allows<br />
optometrists to identify an ophthalmologist that<br />
may meet their patient’s need, refer them using a<br />
digital system and securely exchange important<br />
clinical data.<br />
Tony Dowd in Supreme Biotechnologies’ algae growing facility<br />
professionals that contains more of the AREDS’<br />
ingredients to help introduce the profession more<br />
slowly to the benefits of astaxanthin, despite his<br />
company’s own research showing not all AREDS’<br />
ingredients are as important as perhaps they<br />
were once thought. For the moment, however, the<br />
company is sticking with the product it has and will<br />
take the educational path with the country’s eye<br />
health professionals, says Dowd.<br />
Astaxanthin is considered a “superantioxidant”—6,000<br />
times more powerful than<br />
vitamin C and 500 times more powerful than<br />
green tea, according to Supreme Biotechnologies’<br />
website. Unlike vitamin C, which can be harmful<br />
at high doses by becoming pro-oxidant, damaging<br />
cells just like free radicals do, it also doesn’t appear<br />
to have any harmful side effects.<br />
But the key difference between astaxanthin and<br />
other antioxidants is that most are either water<br />
soluble or fat soluble, which restricts which parts<br />
of the body they reach. Astaxanthin is both, so it<br />
can reach outside and inside cells…it can penetrate<br />
the blood-brain and thus the blood-eye barrier, says<br />
Dowd. “It can sit across the membrane as it has<br />
polar and non-polar parts to it; and because it can<br />
AREDS2<br />
The Age-Related Eye Disease Study 2 (AREDS2)<br />
was a multi-centre, randomised trial designed<br />
to assess the effects of oral supplementation<br />
of macular xanthophylls (lutein and<br />
zeaxanthin) and/or long-chain omega-3<br />
fatty acids (docosahexaenoic acid) [DHA] and<br />
eicosapentaenoic acid [EPA] on the progression<br />
to advanced age-related macular degeneration<br />
(AMD). An additional goal of the study was to<br />
assess whether forms of the AREDS nutritional<br />
supplement with reduced zinc and/or no<br />
beta-carotene works as well as the original<br />
supplement in reducing the risk of progression<br />
to advanced AMD. Enrolment concluded in <strong>Jun</strong>e<br />
2008 and participants were followed between<br />
five and six years. Source, and for more:<br />
www.areds2.org/<br />
The Australian roll-out began in April and<br />
now numbers some 250 optometry practices<br />
and 150 ophthalmologists, and numbers are<br />
growing daily, said Dr Taylor. “We developed<br />
the system alongside the big corporates: Bupa<br />
Optical, Luxottica’s OPSM and Laubman and<br />
Pank, and Specsavers have all been involved<br />
in testing.” But the Oculo team are now keen<br />
to get as many independents on board as<br />
possible, and have set a “really achievable”<br />
monthly subscription price for the product of<br />
just US$99, she said. “This system needs to be<br />
accessible because the patient benefit comes<br />
from the connectedness of the network.”<br />
Dr Taylor noted that while there have been<br />
a number of digital advances in treatment<br />
programmes, an update in communication<br />
practises is well overdue. “Eye care<br />
professionals usually communicate by fax,<br />
handwritten letter and – even more worryingly<br />
– email and Facebook. The need for a safe, secure<br />
and confidential platform for collaboration was<br />
great.”<br />
The amount of time involved in handwritten<br />
communications can cause both optometrists<br />
and patients ongoing stress, she added. “It can<br />
get in, it can get to the free radicals that are sitting<br />
there—caused by ultraviolet light and pollution,<br />
and everything else—and cause the damage.”<br />
Further studies have shown the benefits of<br />
astaxanthin in slowing and even reducing cataract<br />
formation, plus there’s a multitude of studies<br />
showing astaxanthin’s benefits combating or<br />
mitigating diabetes, epilepsy, dementia, heart<br />
disease and even stroke.<br />
“That’s the best thing about the product,” says<br />
Dowd. “It not only gives you all the eye health<br />
benefits, it also gives you all the other benefits as<br />
well. There’s a huge market potential.”<br />
Dowd is in the process of collating a number<br />
of peer-reviewed studies into a dossier for eye<br />
health professionals, which he will be distributing<br />
shortly. He’s also talking to a couple of people<br />
about running a proper clinical study, involving<br />
a statistically significant number of patients, to<br />
clinically back up the company’s qualitative data.<br />
“This is a world with an aging population, where<br />
more and more people are spending more and<br />
more time on their screens. It’s a huge issue. And,<br />
yes, we’re in business to make money, but the stuff<br />
works; it really works.”<br />
SUPREME BIOTECHNOLOGIES<br />
Supreme Biotechnologies is a Nelsonbased,<br />
private company that specialises<br />
in the production of bioactive compounds<br />
derived from micro-algae, specifically natural<br />
astaxanthin. Developed in partnership with<br />
researchers at the Cawthorn Institute, the<br />
company’s algae-growing facility is a unique,<br />
fully-enclosed, indoor environment, providing<br />
the perfect nutrient and light conditions for<br />
the algae, and ensuring the algae is free from<br />
environmental contaminants. The process has<br />
the added benefit of consuming CO 2<br />
while<br />
releasing oxygen.<br />
The company was a finalist in the 2015 and<br />
2014 New Zealand Innovator Awards and has<br />
attracted significant investment from New<br />
Zealand’s angel investment community.<br />
Oculo Screen Shot<br />
take months to even receive an acknowledgement<br />
a referral has been received. Getting feedback<br />
regarding a referral within hours or days takes a<br />
great weight off optometrists’ minds, to know their<br />
duty of care is appropriately discharged and the<br />
patient is likely to come back to them.” ▀<br />
Dr Ilva Rupenthal receives her Excellence Award from HRC’s<br />
Professor Kath McPherson<br />
In a glittering event at Auckland University<br />
on 4 May, Dr Ilva Rupenthal became one<br />
of the first researchers to receive a Health<br />
Research Council (HRC) Celebrating Research<br />
Excellence Award.<br />
Dr Rupenthal, a senior lecturer with the<br />
University’s Department of Ophthalmology<br />
and director of the Department’s Buchanan<br />
Ocular Therapeutics Unit (BOTU), was<br />
honoured as an emerging researcher who has<br />
made an outstanding contribution to health<br />
research.<br />
HRC chief executive, Professor Kath<br />
McPherson, presenting the award, said that<br />
since completing her PhD eight years ago, Dr<br />
Rupenthal has shown excellent progression in<br />
her research career.<br />
Dr Rupenthal received a HRC Emerging<br />
Researcher First Grant followed by the HRC’s<br />
prestigious $500,000 Sir Charles Hercus<br />
Fellowship, before being appointed inaugural<br />
director of the BOTU.<br />
“Jumping the hurdle from being a<br />
postdoctoral research fellow under another<br />
principle investigator to an independent<br />
researcher can be quite difficult especially<br />
with the limited funding opportunities<br />
available to emerging researchers,” said Dr<br />
Rupenthal. “These two HRC grants supported<br />
me immensely in overcoming this hurdle and<br />
becoming an independent research leader and<br />
internationally recognised expert in the area<br />
of ocular drug delivery.”<br />
The HRC also honoured New Zealand’s preeminent<br />
brain researcher, Professor Richard<br />
Faull, director of the Centre for Brain Research<br />
at the University of Auckland and co-director<br />
of the Brain Research New Zealand Centre for<br />
Research Excellence.<br />
Since being awarded his first HRC project<br />
grant 25 years ago, Professor Faull has gone<br />
on to lead a further three more HRC-funded<br />
projects and four HRC-funded programmes in<br />
the area of neurodegeneration in the human<br />
brain. He was also awarded the prestigious<br />
Liley Medal in 2005.<br />
The awards ceremony was the first of a series<br />
of events in partnership with New Zealand’s<br />
leading institutions, celebrating HRC’s 25th<br />
anniversary.<br />
HRC grants awarded<br />
In related news, Dr Jie Zhang and Dr<br />
Stuti Misra at the University of Auckland<br />
were awarded HRC grants recognising the<br />
importance of their projects to eye health.<br />
Dr Zhang received an HRC emerging<br />
researcher first grant, to carry out a study to<br />
determine the potential of adult stem cells<br />
in the transition zone for corneal endothelial<br />
transplants. Theoretically, using transition<br />
zone cells each future human donor cornea<br />
could provide grafts for several transplants,<br />
explained Dr Zhang.<br />
Dr Misra also received an HRC emerging<br />
researcher first grant for a project entitled<br />
Corneal nerve microstructural changes in<br />
diabetes. This study looks to monitor changes<br />
in the eye that occur in morbidly obese<br />
patients using weight-loss or bypass surgery to<br />
control their diabetes. ▀<br />
6 NEW ZEALAND OPTICS <strong>Jun</strong>e <strong>2016</strong>
NEW ZEALAND’s<br />
ONLY NATURAL ASTAXANTHIN<br />
AstaSupreme ® Advanced Eye Care, the first eye care formulation to combine the<br />
power of Astaxanthin with Lutein, Zeaxanthin and Saffron to create a powerful<br />
carotenoid complex to boost all aspects of eye health and protect the eye,<br />
whatever age you are.<br />
For eye health professionals who want to know more about AstaSupreme ®<br />
Advanced Eye Care please contact Supreme Biotechnologies on 0800 289-278 or<br />
email info@astasupreme.co.nz or refer to www.astasupreme.co.nz.<br />
For eye health professionals who would like to become a supplier, please contact<br />
Pharmabroker on 09 415 5050 or email ruth@pharrmabroker.co.nz<br />
<strong>Jun</strong>e <strong>2016</strong> NEW ZEALAND OPTICS<br />
Always read the label. Use only as directed. If symptoms persist, see your healthcare professional.<br />
7
Ocular Therapetics Conference<br />
New Ocular Therapeutics Conference a success<br />
The inaugural Ocular Therapeutics Conference attracted nearly 350 delegates<br />
Professor Charles McGhee, head of the<br />
Department of Ophthalmology at the<br />
University of Auckland, opened the inaugural<br />
Ocular Therapeutics Conference on the 10 April in<br />
Auckland with gusto, announcing that with nearly<br />
350 attendees, it was already one of, if not the<br />
biggest, ocular event in New Zealand.<br />
Invited specialist speakers delivered rapid-fire<br />
lectures on a wide variety of topics designed<br />
to empower, educate and enhance the work<br />
of attending optometrists, ophthalmologists,<br />
therapeutic nurses, pharmacists and others.<br />
Organisers, Professor McGhee and Drs Trevor Gray<br />
and Ilva Rupenthal, director of the Buchanan Ocular<br />
Therapeutics Unit (BOTU), said with the success of<br />
this inaugural Ocular Therapeutics Conference it<br />
will now become a regular annual feature on the<br />
industry’s continuing education calendars.<br />
NZ Optics was there to record the highlights<br />
of the day.<br />
8 NEW ZEALAND OPTICS <strong>Jun</strong>e <strong>2016</strong><br />
History and breaking down differences<br />
The first presentation was appropriately given by<br />
Dr Rupenthal. She provided an historical overview<br />
of medications and the eye, noting the first record<br />
of treating eyes with eye-drops dated back to<br />
Babylon, around 2250 BC. Acacia was used in<br />
Ancient Egypt to reduce eyelid inflammation,<br />
while Cleopatra used Atropa Belladonna (Deadly<br />
Nightshade) to make her pupils larger to enhance<br />
her beauty.<br />
Later Dr Rupenthal also discussed the difference<br />
between various drops given as gels, ointments,<br />
solutions and suspensions, as well as the<br />
importance of using them correctly. Suspensions<br />
must be shaken, she said, as the active particles<br />
sink to the bottom, while obstructing the nasal<br />
passage for five minutes after applying drops can<br />
result in a far better retention time.<br />
Professor McGhee discussed how topical<br />
eye-drops get into the eye, noting that when<br />
CLINICAL DESKTOP<br />
Free to you from NZ Optics – Clinical Desktop<br />
No more tussling over NZ Optics each month, just sign up to our<br />
monthly e-newsletter, Clinical Desktop. Stay up-to-date with the latest<br />
research from our own Eye on Ophthalmology, plus the often amusing<br />
look at the world of CLs from our well-known columnist Alan Saks. It’s<br />
free to sign up and you don’t have to be an existing subscriber.<br />
Simply email your full name and occupation to info@nzoptics.co.nz,<br />
put ‘Clinical Desktop’ in the subject box, and you’re on the list.<br />
prescribing it’s essential clinicians focus on the ease<br />
of application and how quickly the drops start to<br />
work. An understanding of pharmacokinetics – the<br />
time and dosage relationship – is also essential as<br />
with some drops there is a point where too much<br />
leads to toxicity. With all, a lot is lost through tears<br />
and spillage, he said.<br />
Dr Gray talked about the role for oral Rx for<br />
Meibomian gland dysfunction and dry dye disease,<br />
noting a 2005 study highlighting the positive<br />
benefits of omega 3 fatty acids – a natural antiinflammatory<br />
– and the negative effects of omega<br />
6s in our diet. When it comes to treating dry eye<br />
beyond dietary considerations, however, Dr Gray<br />
highlighted a study on oral azithromycin, which<br />
showed it was far more effective than those treated<br />
with the more commonly used doxycycline, with<br />
side effects in just 4%.<br />
Dr Andrew Thompson closed the morning session<br />
with his talk, The Ingredients You Don’t Know About.<br />
A pharmacist turned ophthalmologist, Dr Thompson<br />
offered a unique perspective on what goes into an<br />
eye drop and why. He talked the audience through<br />
surfactants, buffers and preservatives and noted<br />
preservatives can cause ocular surface disease,<br />
especially when used over long periods of time such<br />
as in the case of glaucoma patients.<br />
Funding drugs, artificial tears and<br />
antibiotics<br />
Professor Colin Green kicked off the second session<br />
after morning tea, with his look at what it takes to<br />
get a drug approved by the US FDA. It costs about<br />
US$350 million to get a new medicine to market, so<br />
it is along and expensive, but well understood path,<br />
he said. Safety and toxicology take time and require<br />
at least one non-rodent species before human trials<br />
can be considered. For devices, the pathway is faster,<br />
while repurposing a drug often allows you to bypass<br />
certain stages, making development faster and<br />
cheaper.<br />
The funding of new medicines in New Zealand<br />
is a contentious issue so it was fascinating to hear<br />
from Sarah Fitt, PHARMAC’s operations director.<br />
PHARMAC’s aim is to get the best health outcomes<br />
for the maximum number of people within the<br />
amount of funding provided. Its focus is on creating<br />
competition to generate cost-savings as it needs<br />
to find $50m a year in savings just to manage the<br />
ever-increasing prescription volume. Fitt admitted<br />
there will never be enough money to fund all<br />
the medicines people want, but each application<br />
is considered on its merits. An ophthalmology<br />
sub-committee, PTAC, advises PHARMAC on eye<br />
medicines.<br />
Associate Professor Jennifer Craig discussed how<br />
to pick the best artificial tear supplements for<br />
individual patients. Dry eye is a complex condition<br />
and simply adding moisture is not the quick fix<br />
we once thought it might be, she said. Highly<br />
viscous supplements can be helpful with moisture<br />
retention, but blur vision, whereas improving diet<br />
to increase natural lipids can be more helpful in the<br />
treatment for those with evaporative dry eye.<br />
Dr Mark Saunders and Dr Penny McAllum then<br />
moved the talk to antibiotics, with Dr Saunders<br />
providing an overview of their action and use, and<br />
Dr McAllum focusing on how they should be used<br />
in two common eye conditions, conjunctivitis and<br />
blepharitis.<br />
Dr Saunders injected some humour into the day<br />
with the unusual case of a 17-year-old boy who was<br />
kicked in the face by a hedgehog. The case posed<br />
several complications, beyond the damage to the<br />
boy’s left eye, as hedgehogs are full of diseases. The<br />
boy’s mother was able to provide Dr Saunders with<br />
the (now deceased) hedgehog for testing and this<br />
allowed Dr Saunders to target the boy’s treatment<br />
so he could make a full recovery.<br />
Dr McCallum shared how the management<br />
of bacterial conjunctivitis is centred around<br />
hygiene, but a short course of antibiotics for more<br />
irritating infections is effective. The most common<br />
treatments are drops, such as Chlorafast or fusidic<br />
acid, with Brolene used sparingly due to potential<br />
toxicity issues and ciprofloxacin reserved for more<br />
serious infections. With posterior blepharitis,<br />
Dr McAllum noted that 40% of patients have<br />
Meibomian gland dysfunction. The appearance<br />
of ‘cylindrical dandruff’ could indicate a Demodex<br />
Kerensa McCamish and Germaine Joblin<br />
Essi Kokkinen, Priyanka Agarwal and Di Huang<br />
Catherine Wong, Bev and Jonathan Payne and Louise Wood<br />
John Adam, Diane Pearson, Dr Trevor Gray and Grant Dabb
OCULAR THERAPEUTICS CONFERENCE SPONSORS<br />
OptiMed NZ<br />
Ophthalmic Instrument Company<br />
Alcon<br />
Corneal Lens Corporation<br />
Designs for Vision<br />
Device Technologies<br />
Abby Long, Lari Dkhar and Ghada Zidan<br />
Kent Napier, Nawras Nabhani and Bharat Raniga<br />
Jonathan Albert, Deanne Jordan, Amy Young and Melanie Lipinski<br />
David Joe checks out OptiMed’s wares with Robert Nyenkamp and Craig<br />
Norman<br />
Alcon’s Deanna Graham and Caroline Perkinson talking to delegates<br />
Shelley Brannigan, Scott Dumbleton, Craig Holmes and Tony Cradwick<br />
Speakers: (back) Drs Sarah Fitt, Hussain Patel, Simon Dean and Trevor Gray, Professor Colin Green, Drs Mark Saunders, Andrew Thompson and Stephen<br />
Best and Professor Charles McGhee (front) A/Prof Jennifer Craig, Drs Ilva Rupenthal, Rasha Altaie, Penny McAllum and Sue Ormonde<br />
mite infestation in the follicles, which can be<br />
treated with a tea tree oil product.<br />
Glaucoma drugs and the dangers of<br />
corticosteroids<br />
Dr Stephen Best kicked off the post-lunch slot with<br />
a personal overview of glaucoma drugs, saying he<br />
tended to recommend a prostaglandin analogue<br />
(the most commonly prescribed medication for<br />
glaucoma currently) at least initially, as they have<br />
few systemic side effects. Other drugs such as beta<br />
blockers, adrenergic agonists, carbonic anhydrase<br />
inhibitors have varying side effects and don’t tend to<br />
be as effective.<br />
Dr Best ended his presentation with a plea to the<br />
audience for more patients for a trial he’s involved<br />
in where a slow-release pellet of the prostaglandin<br />
analogue Bimatoprost is injected into the anterior<br />
chamber. If successful this will replace frequent eye<br />
drop application. Every patient is different and we<br />
need to have a number of options available in order<br />
to treat them all well, he said.<br />
Dr Hussain Patel continued the glaucoma theme<br />
with an overview of how best to systematically treat<br />
glaucoma. He preferred to set a target IOP, based<br />
on the glaucoma’s severity and the patient’s life<br />
expectancy. Important management considerations<br />
include patient education about diet and lifestyle,<br />
the different medications and their side effects,<br />
selective laser trabeculoplasty (SLT) and surgery.<br />
A flow chart approach works best for identifying<br />
the best treatment, though initially Dr Patel also<br />
said he favours a prostaglandin analogue, with<br />
beta blockers added or swapped in if the results<br />
aren’t as good as hoped. Early glaucoma patients<br />
need to be clinically assessed at least once every 12<br />
months; moderate glaucoma every six months; and<br />
advanced glaucoma every four months.<br />
Professor McGhee then presented an amusing<br />
overview of topical ophthalmic corticosteroids,<br />
beginning with a warning that, on the whole,<br />
corticosteroids are “the devil’s work” as they<br />
tended to be the go-to option for most. Yes,<br />
they are important and often sight-saving antiinflammatory<br />
drugs, he said, but they are also “a<br />
blunderbuss therapy” with significant side effects,<br />
including cataract, glaucoma and severe microbial<br />
infections. In summary, steroids should only be used<br />
when there’s a firm diagnosis and, never if any sort<br />
of infection is suspected.<br />
Dr Sue Ormonde, a former Corneal Fellow of<br />
Professor McGhee’s, continued the corticosteroid<br />
theme by looking at their use in practice. This is<br />
not easy in a 12-minute presentation, she said, as<br />
it takes years of experience to use steroids well<br />
– a concern backed up by several slides of eyes<br />
irrevocably damaged by poor steroid use. You have<br />
to be sure of your diagnosis and the specifics of<br />
that diagnosis, said Dr Ormonde. Correct use also<br />
depends on the specifics of the disease, how you<br />
are going to treat it and how it progresses. Once a<br />
diagnosis is made, you need to “hit hard” and, if the<br />
steroids don’t do what you want them to, stop, keep<br />
calm and reassess, she said.<br />
Steroid alternatives, myopia, more on<br />
glaucoma and the future<br />
Opening the final session, Dr Simon Dean’s<br />
presentation was a much needed look at the<br />
alternatives to corticosteroids and how to avoid<br />
their unwanted effects.<br />
In general steroids should not be used for a long<br />
time and should be avoided for things like allergy<br />
as patients can get too easily hooked on them as<br />
they work so well, he said. Alternatives include mast<br />
cell stabilisers, non-steroidal anti-inflammatory<br />
medications (NSAIDS), such as Voltaren, and<br />
cyclosporin, which reduces the activity of the<br />
immune system by interfering with the activity of<br />
T-cells (lymphocytes).<br />
Dr Rasha Altaie provided a fascinating review<br />
of studies on the effectiveness of dilute topical<br />
atropine in reducing the progression of childhood<br />
myopia. Atropine use is not new, she reminded the<br />
audience, with Atropa Belladonna used for myopia<br />
treatment since the 19th century. In summary, Dr<br />
Altaie said despite the fact we don’t fully know<br />
how it works, studies show atropine 0.01% does<br />
slow the progression of myopia, in children with<br />
mild to moderate myopia, by up to 50%, with no<br />
obvious side effects, but it doesn’t stop it. Prevention<br />
is far better than cure, however, she said, with<br />
many studies now showing how important it is for<br />
children to stay away from screens and play outside<br />
for at least three hours a day.<br />
Professor Helen Danesh-Meyer returned to the<br />
topic of glaucoma with her presentation on common<br />
glaucoma drop side-effects. All of these are a<br />
problem for compliance as patients often don’t have<br />
any problems when glaucoma is first identified, she<br />
said. “Patients are well until the come to see us and<br />
then we make them unwell with our drugs, so the<br />
bar is very different for a silent disease.”<br />
Practitioners need to have a “high index of<br />
Get to the main<br />
cause of dry,<br />
irritated eyes*<br />
How does Optrex ActiMist work?<br />
Optrex ActiMist contains<br />
liposomes (tiny bubbles fi lled with<br />
moisture) that migrate across the<br />
surface of the eyelid and collect<br />
at the edges of the eye.<br />
Hygienic. Can be used<br />
by multiple people<br />
Lasts 6 months<br />
after opening<br />
These liposomes mix with natural<br />
lipids on the eyelid.<br />
Won’t smudge<br />
make-up<br />
ActiMist liposomes<br />
ActiMist liposomes<br />
When the eyes are open the new<br />
lipid mixture spreads over the<br />
whole tear fi lm, and helps fi ll the<br />
gaps to restore the damaged<br />
lipid layer.<br />
Convenient and<br />
portable<br />
Suitable for use<br />
with contact lenses<br />
suspicion” as side effects can be extremely varied.<br />
For example, prostaglandin analogues can change<br />
iris colour and cause hair growth—great for<br />
eyelashes, less for other facial hair—and cause some<br />
pre-existing conditions, such as HSV, to flare up<br />
again. Beta blockers have a number of well-known<br />
systemic side effects, but can also cause impotence,<br />
depression and even nightmares, while Brimonidine<br />
can cause fatigue and follicular conjunctivitis. If the<br />
patient develops unsatisfactory side effects, stop<br />
the medication, reassess and identify an alternative,<br />
such as SLT, she said.<br />
Dr Ilva Rupenthal closed the conference with<br />
a look into the future, focusing on the work of<br />
the BOTU and some of the most prominent and<br />
interesting ocular therapeutics potentials out<br />
there. This included a cationic nanoemulsion<br />
of ciclosporin from Santen; a semi-fluorinated<br />
alkane eye drop by Novaliq that is currently being<br />
investigated by BOTU; mucus penetrating particles<br />
from Kala Pharmaceuticals; and Ocular Therapeutix’<br />
drug-delivering punctum plugs. Other interesting<br />
developments include Helios, a silicone ring loaded<br />
with the anti-glaucoma drug bimatoprost, which<br />
is inserted in the eye. BOTU is currently involved in<br />
several therapeutic clinical trials to identify novel<br />
new agents and drug delivery vehicles, including a<br />
number of stimuli-responsive drug delivery systems<br />
involving ultrasound- and laser-activated particles as<br />
well as an implant activated by a small current.<br />
Dr Rupenthal closed the conference by thanking<br />
everyone who had been involved in making it<br />
happen, especially Dr Trevor Gray and Professor<br />
Charles McGhee, all the attendees and the<br />
exhibitors (see box) for their support. ▀<br />
4UP TO<br />
HOURS<br />
RELIEF 2<br />
CLINICALLY PROVEN<br />
Optrex ActiMist – clinically proven to work<br />
Natural lipids<br />
Order stock for your practice today<br />
FREE CALL 0800 393 564 EYELOGIC<br />
www.optrex.co.nz optrex@eyelogic.com.au<br />
Always read the label. Use only as directed. If symptoms persist, see your healthcare professional. †When wearing make-up, it is recommended to apply from 20cm. *Due to disturbed lipid layer of the tear fi lm. References:<br />
1. Lee S et al. Klin Monatsbl Augenheilkd 2004; 221:1–12. 2. Khaireddin R, Schmidt KG. Klin Monatsbl Augenheilkd. 2010; 227: 128-134. 3. Pult H et al. Contact Lens Anterior Eye 2012, 35:203-207. Reckitt Benckiser, Auckland. TAPS DA1541<br />
<strong>Jun</strong>e <strong>2016</strong><br />
NEW ZEALAND OPTICS<br />
9
Focus<br />
on Business<br />
IRD INVESTIGATIONS<br />
Who are they targeting and what to do<br />
if you get a query<br />
BY DAVID PEARSON AND TIM ZONNEVELD*<br />
Over the past few years the<br />
Government has been steadily<br />
increasing budget funding for Inland<br />
Revenue investigations, with a current budget<br />
allocation of $74 million over five years<br />
(expected to yield an 800% return). While<br />
the focus has been more on aggressive tax<br />
planning and hidden economy initiatives, this<br />
is also having a flow on effect with initiatives<br />
such as the basic compliance package (BCP)<br />
information requests, which you may have<br />
heard of or even received.<br />
There are a number of different reasons<br />
Inland Revenue may select you for an audit.<br />
Some of the more common reasons our BDO<br />
tax team see include:<br />
i. Your past compliance history (ie. have you<br />
been filing returns and making payments<br />
on time?).<br />
ii. Checking your records as a result of an<br />
audit of another related taxpayer, or<br />
an unrelated taxpayer you have had<br />
transactions with.<br />
iii. Examining a particular issue facing groups<br />
of taxpayers.<br />
Past compliance history<br />
This is often one of the more common reasons<br />
for an audit and is the easiest to remedy.<br />
Maintaining a good compliance history with<br />
Inland Revenue goes a long way to both<br />
reducing the risk of an audit and also putting<br />
you on an equal footing in the event an audit<br />
does occur.<br />
The good compliance history should<br />
extend beyond simply filing the returns<br />
and making the payments on time. The<br />
importance of keeping good, well-referenced<br />
documentation to support the tax positions<br />
adopted also demonstrates you have<br />
taken reasonable care and can be crucial<br />
in ensuring a smooth process should an<br />
audit arise. It goes without saying that your<br />
accountant and/or tax adviser should play an<br />
important role in assisting here.<br />
Checking records with another taxpayer<br />
The most common occurrence in this regard<br />
is where other companies or shareholders in a<br />
group are incorporated into an audit of one of<br />
the other members. Selection for an audit as a<br />
result of an audit of an unrelated party arises<br />
less often.<br />
While taxpayers can control their own<br />
tax position and compliance history, they<br />
unfortunately cannot control those of the<br />
people they do business with. In these<br />
situations, you will need to trust and rely on<br />
your own documentation and compliance<br />
history to minimise your risk.<br />
Examining particular issues facing groups of<br />
taxpayers<br />
If you have followed recent media reports<br />
on tax audits you will have noticed Inland<br />
Revenue’s particular focus on the hospitality<br />
and, more recently, the trade and construction<br />
industries. In this regard Inland Revenue is<br />
targeting the “hidden economy” or “cash<br />
transactions” which are not reported or<br />
included in tax returns to Inland Revenue.<br />
The landmark case Penny and Hooper<br />
v Commissioner of Inland Revenue is an<br />
excellent example of Inland Revenue’s<br />
approach to groups of tax payers, in this case<br />
orthopaedic surgeons. The Court unanimously<br />
found that the two Christchurch surgeons,<br />
who were paid artificially low salaries, via their<br />
business structures, were avoiding tax. As an<br />
outcome, the Inland Revenue broadened their<br />
focus to a wide range of professional taxpayer<br />
groups with significant ramifications.<br />
What to do if you get a query<br />
It goes without saying that the first thing you<br />
should do is contact your accountant and/or<br />
tax adviser, however some other helpful tips<br />
are as follows:<br />
1. Don’t panic! Information requests and<br />
audits are becoming more common as<br />
a result of increased investment by the<br />
government, so don’t take it personally.<br />
2. Comply with all requests in a timely<br />
manner<br />
3. Maintain good communication. Audits<br />
and information requests typically occur<br />
at the busiest times so, if you think it<br />
will be difficult to supply the requested<br />
information in time, it is important to<br />
discuss this with the investigator as soon as<br />
possible and arrange for more appropriate<br />
deadlines. In our experience most Inland<br />
Revenue investigators are quite reasonable<br />
and accommodating in this regard. Make<br />
sure your key personal, such as payroll<br />
or IT managers, aren’t on holiday when<br />
considering the best time for the audit<br />
to take place. In some cases, Inland<br />
Revenue will be more relaxed in relation to<br />
extending deadlines if it can receive at least<br />
some information before the deadline. This<br />
may give the investigator confidence and<br />
ensures that internally, things will not be<br />
left to the last minute.<br />
4. Consider making a voluntary disclosure. A<br />
voluntary disclosure can deliver a reduction<br />
of penalties. It will often be as a result of<br />
an internal review of the tax matters that<br />
are the subject of the audit; and perhaps<br />
a review of other tax matters that may<br />
be included if the scope of the audit is<br />
expanded. Assistance with such reviews<br />
may be provided by your accountant and/<br />
or tax adviser and the findings from such<br />
reviews may be provided to or requested<br />
by the Inland Revenue. If done well it will<br />
demonstrate you are serious about tax<br />
compliance, and may result in less Inland<br />
Revenue time on-premises.<br />
So should you be worried?<br />
The fact that you are being audited or asked<br />
for information does not mean that you<br />
are necessarily ‘in trouble’. Even if you are<br />
in what Inland Revenue might consider to<br />
be a ‘high-risk category’, it is important to<br />
remember that it is an individual situation<br />
that matters. Provided you have a good<br />
compliance history, have good records and<br />
work with your accountant/tax adviser to<br />
maintain good communication with Inland<br />
Revenue, the risk review or audit should be a<br />
relatively smooth process. ▀<br />
ABOUT THE AUTHORS:<br />
* David Pearson is<br />
anaging partner in the<br />
Napier firm of BDO,<br />
a global network of<br />
chartered accountants<br />
and advisers. He has a<br />
specialisation in advice to<br />
the medical sector.<br />
* Tim is a partner in the<br />
Taxation Services division<br />
of BDO in Auckland.<br />
conference <strong>2016</strong><br />
Registrations are now open for the annual<br />
Save Sight Society one-day conference on 26<br />
August in Tauranga.<br />
The event is shaping up to be a “must-do” date on<br />
the calendar for New Zealand based practitioners,<br />
says Dr Sam Kain, this year’s conference convenor.<br />
“It’s our main fundraiser and it’s open to the entire<br />
optometry and ophthalmology community. It’s<br />
quite different to other events as it has a very ‘local<br />
flavour’ peculiar to NZ.”<br />
A smaller, more personal meeting than many<br />
other conferences and symposiums, the Save<br />
Sight Society conference focuses specifically on<br />
issues facing those practicing in Aotearoa, with a<br />
series of short presentations and the floor always<br />
open to questions. This year the presentations<br />
will centre around updates across three main subspecialities—cornea,<br />
retina and uveitis.<br />
People aren’t afraid to ask questions at the<br />
Save Sight Society conference, so much of the<br />
education comes from the floor, says Dr Kain. “The<br />
speaker really just opens the discussion. You don’t<br />
need to be an expert to join in; the atmosphere<br />
is friendly and open to new ideas. It’s a great<br />
networking event.”<br />
Dr Kain says it’s also a great event to talk<br />
about the idiosyncrasies of local DHBs, funding<br />
streams and issues relating to the very specific<br />
demographics of New Zealand, such as the large<br />
Maori and Pasifika communities. The constraints<br />
of practicing in a small and isolated island with<br />
limited funds and unusual challenges also create<br />
some very innovative responses, and discussion of<br />
this nature will run freely, he says.<br />
“Practice is unique in New Zealand, even<br />
compared to Australia. At some of the bigger<br />
international meetings it can be hard to have<br />
open discussions about things specific to us,<br />
because it’s not relevant to the wider audience.”<br />
The Save Sight Society continues to be one of<br />
the biggest, non-government funding agencies in<br />
New Zealand, having given more than $700,000 in<br />
research grants in recent years. For more visit<br />
www.savesightsociety.org.nz. ▀<br />
ODOB’s new guidelines on oral<br />
medications<br />
The Optometrists and Dispensing Opticians’<br />
Board (ODOB) new guidelines for prescribing<br />
medications are now available online. The<br />
board has been working on this for some time and<br />
would like to encourage all certified therapeutic<br />
pharmaceutical agent (TPA) optometrists to<br />
familiarise themselves with the documents, says<br />
Lindsey Pine, ODOB registrar.<br />
“Regulations were changed in 2014 giving TPA<br />
optometrists more freedom to prescribe, rather than<br />
having to stick to an approved list of medications.<br />
“It was recognised clear guidelines were<br />
needed for more high-risk medications and<br />
medicines with contraindications. They have<br />
now been published, and we will be making TPA<br />
optometrists and dispensing opticians aware they<br />
are available.”<br />
The new guidelines focus specifically on allergic<br />
eye disease, herpes simplex virus, keratitis and<br />
herpes zoster ophthalmicus. More guidelines are<br />
expected to be added soon.<br />
The new guidelines can be accessed by visiting:<br />
www.odob.health.nz/cms_display.<br />
php?sn=74&st=1&pg=1529 . ▀<br />
Visionz tackles low vision<br />
Visionz <strong>2016</strong> will include a one-day low vision<br />
conference on Friday 14 October as part of a<br />
comprehensive educational programme for<br />
optometrists, practice managers and other optical<br />
staff alongside its industry showcase.<br />
The biennial conference, organised by the<br />
New Zealand Optical Wholesalers Association<br />
(NZOWA) and run in tandem with the Association<br />
of Dispensing Opticians (ADONZ), is being held on<br />
Friday 14th to Sunday 16th October at the Ellerslie<br />
Events Centre in Auckland.<br />
Planning is well under way with 60 exhibition<br />
booths displaying all that’s new in the industry<br />
including frames, sunglasses, lenses, equipment,<br />
accessories, software and services, while the<br />
education programme, Eduvisionz, already includes<br />
an impressive slate of speakers.<br />
On the low vision side this includes Dr Mike<br />
O’Rourke, ophthalmologist at Tauranga Eye<br />
Specialists, who recently carried out a lifechanging<br />
procedure, using an intraocular<br />
mini-telescope implant, (see story P4); Professor<br />
Stephen Lord, senior principal research fellow<br />
from the Falls and Balance Research Group from<br />
Sydney, who will address Falls in Older People:<br />
Visual Risk Factors and Intervention Strategies;<br />
and Dr Alan Johnston, a low vision specialist from<br />
Melbourne, who will discuss his recently updated,<br />
sliding scale logMAR visual acuity calculator,<br />
which includes ETDRS scoring principles, now<br />
widely used for monitoring any vision gain or<br />
loss with intra-vitreal injection of anti-VEGF, and<br />
Telescopes for low vision: principles, practice and<br />
rationales for clinical choice.<br />
Other sessions include:<br />
••<br />
The latest developments in technology and<br />
innovation in low vision products<br />
••<br />
Incorporating low vision clinics into a busy<br />
optometry practice<br />
••<br />
Identifying a person’s low vision needs and<br />
rehabilitation goals<br />
••<br />
Sharing important strategies for daily life<br />
••<br />
The latest research into the use of mobility<br />
scooters, digital devices and neurological vision<br />
impairment<br />
••<br />
The current development of an occupationbased<br />
low vision model incorporating the level 8<br />
Visionz<br />
2014 <strong>2016</strong><br />
postgraduate curriculum in low vision for allied<br />
health professionals<br />
••<br />
The Blind Foundation’s Prevalence Study Work<br />
and the Level 7 Vision Rehab diploma to be<br />
launched in 2017<br />
On Saturday, the focus will move to the business of<br />
optometry with speakers addressing the commercial<br />
aspects of running a business in today’s competitive<br />
environment, says Gary Edgar, NZOWA president.<br />
“We are planning to deliver an event to suit the<br />
changing needs of our clients and the broader<br />
industry in general.”<br />
Speakers include Juanita Neville-Te Rito from The<br />
Retail Collective who will share insights drawn from<br />
her 25-year career in retail, and her personal passion<br />
for shopping, including five key trends in retail<br />
that any retail business owner should be aware of;<br />
business mentor, Tanya Unkovich, who will present<br />
on how to use your life experiences to know and<br />
get what you want in life; and John Saywell, CEO of<br />
Christchurch software and consulting company RPM<br />
Retail, who will discuss how to analyse your optical<br />
practice’s strengths, weaknesses, opportunities and<br />
threats. Other topics include:<br />
••<br />
Coming to terms with the new Health & Safety<br />
laws<br />
••<br />
The pros and cons of social media and whether a<br />
practice can benefit from incorporating a social<br />
media platform into its marketing strategy<br />
••<br />
Picking the best team and getting it right from<br />
the start<br />
Another attraction at Visionz <strong>2016</strong> will be the<br />
opportunity to register for a St John’s Basic Life<br />
Support course, that teaches essential life-saving<br />
skills, on the Saturday afternoon. Participants will<br />
receive a NZQA 6401/6402 acknowledgment at the<br />
end of the 4-5 hour course.<br />
Visionz and Eduvisionz, as well as being held in<br />
conjunction with ADONZ’s annual conference,<br />
will also incorporate the International Opticians<br />
Association Annual Meeting, which is being hosted<br />
for the first time in New Zealand. A Visionz ‘Happy<br />
Hour’ has also been organised for late on the Friday<br />
afternoon for all delegates.<br />
Registration for Visionz and Eduvisionz will open<br />
in July. Keep reading NZ Optics magazine for more<br />
information or email: contact@nzowa.org.nz. ▀<br />
10 NEW ZEALAND OPTICS <strong>Jun</strong>e <strong>2016</strong>
All<br />
shades<br />
of life<br />
Coming<br />
soon!<br />
Adapt to all light conditions<br />
• Stabilight Technology ensures consistent performance in different climates and seasons<br />
• Excellent contrast and glare reduction with Sensity’s deep, natural colours<br />
• Exceptional optical quality and durability due to Photochromic Precision Technology<br />
• Available across a wide product range in PAL, single vision and bifocal<br />
• Available in grey, brown and green.<br />
P: 09 630 3182 | E: hapl_cs_nz@hoya.com | www.hoyalens.com.au/sensity<br />
<strong>Jun</strong>e <strong>2016</strong><br />
NEW ZEALAND OPTICS<br />
11
Focus on<br />
Eye Research<br />
SMILE and pseudophakia<br />
CLINICAL OUTCOMES AFTER SMILE<br />
AND FEMTOSECOND LASER-ASSISTED<br />
LASIK FOR MYOPIA AND MYOPIC<br />
ASTIGMATISM: A PROSPECTIVE<br />
RANDOMISED COMPARATIVE STUDY.<br />
Liu M; Chen Y; Wang D; Zhou Y; Zhang<br />
X; He J; Zhang T; Sun Y; Liu Q.<br />
Cornea. 35(2):210-6, <strong>2016</strong> Feb<br />
Review: This prospective, randomised,<br />
comparative study compared the<br />
clinical outcomes of small-incision<br />
lenticule extraction (SMILE) and<br />
femtosecond laser-assisted LASIK (FS-<br />
LASIK) for the correction of myopia and<br />
myopic astigmatism. SMILE surgery<br />
was performed in 113 eyes with a<br />
mean spherical equivalent (MSE) of<br />
-5.22 +/- 1.70D, and FS-LASIK was<br />
performed in 84 eyes with an MSE of<br />
-5.18 +/- 1.93D. At six months 97%<br />
of SMILE eyes, and 100% of FS-LASIK<br />
eyes were within +/- 0.5D of the<br />
target refraction, with no statistically<br />
significant difference. There were also<br />
no statistically significant differences<br />
between the two groups in terms of<br />
astigmatic correction. At six months<br />
96% of SMILE eyes, and 99% of<br />
FS-LASIK eyes achieved uncorrected<br />
visual acuity of 20/20 or better, with<br />
no statistically significant difference<br />
between the two groups. There<br />
were also no statistically significant<br />
differences between the groups<br />
regarding loss of best corrected visual<br />
acuity, with loss of one line or more in<br />
6% of the SMILE group, and 5% of the<br />
FS-LASIK group. Looking at wavefront<br />
aberration at six months, the SMILE<br />
group had statistically significantly<br />
lower induced rates of spherical<br />
aberration than the FS-LASIK group.<br />
Comment: SMILE is the latest advance<br />
in corneal refractive surgery. In<br />
comparison to LASIK, no corneal flap<br />
is created, and this has already been<br />
shown to result in a lower rate of<br />
dry-eye post-operatively, as well as<br />
potentially reducing the risk of postoperative<br />
keratectasia. This prospective<br />
randomised study indicates visual<br />
outcomes between the two treatments<br />
are statistically similar, and that<br />
induced rates of spherical aberration<br />
are statistically lower with SMILE.<br />
COMBINED SMALL-INCISION<br />
LENTICULE EXTRACTION AND<br />
INTRASTROMAL CORNEAL COLLAGEN<br />
CROSSLINKING TO TREAT MILD<br />
KERATOCONUS: LONG-TERM<br />
FOLLOW-UP.<br />
Graue-Hernandez EO; Pagano GL;<br />
Garcia-De la Rosa G; Ramirez-Miranda<br />
A; Cabral-Macias J; Lichtinger A; Abdala-<br />
Figuerola A; Navas A.<br />
Journal of Cataract & Refractive Surgery.<br />
41(11):2524-32, 2015 Nov.<br />
Review: This prospective interventional<br />
case series looked at the visual,<br />
refractive, and topographic outcomes<br />
of sequential, same-day smallincision<br />
lenticule extraction (SMILE)<br />
and intrastromal corneal collagen<br />
crosslinking (CXL) in eyes with mild<br />
keratoconus. Fifteen eyes with forme<br />
fruste keratoconus and/or irregular<br />
corneas, were treated with SMILE<br />
followed by intrastromal injection<br />
of riboflavin inside the pocket, and<br />
then 30 minutes of Ultraviolet A light<br />
with a wavelength of 370 nm to 3<br />
mW/cm(2). The mean age was 29.5<br />
years +/- 5.5 (SD), and patients were<br />
followed for 24 months. Pre-operative<br />
uncorrected distance visual acuity<br />
improved from Snellen 20/796 to<br />
Snellen 20/26 post-operatively, which<br />
was statistically significant. Bestcorrected<br />
distance visual acuity did<br />
not change significantly. The spherical<br />
equivalent improved from -4.3 +/-<br />
REVIEWED BY DR SUE ORMONDE*<br />
1.02D preoperatively to 0.2 +/- 0.66D<br />
postoperatively, and 100% of eyes were<br />
within +/- 1.0D of refractive target.<br />
With regards to complications, all<br />
eyes exhibited corneal haze initially<br />
(as expected with CXL), but this had<br />
cleared in all eyes by three months.<br />
One eye lost two lines of best corrected<br />
visual acuity due to a partial lenticule.<br />
No cases of progressive ectasia were<br />
noted.<br />
Comment: By preserving the<br />
biomechanically more stable anterior<br />
layers of the cornea, SMILE potentially<br />
offers a reduced risk of creating<br />
ectasia or promoting progression of<br />
keratoconus in abnormal corneas.<br />
Combining this with CXL may offer a<br />
safe predictable refractive treatment<br />
for patients with mild keratoconus<br />
who cannot be corrected with glasses,<br />
and who are intolerant of contact<br />
lenses. More prolonged follow-up and<br />
larger samples are needed to confirm<br />
the findings.<br />
COMPARISON OF CONVENTIONAL<br />
VERSUS CROSSED MONOVISION IN<br />
PSEUDOPHAKIA.<br />
Kim J; Shin HJ; Kim HC; Shin KC.<br />
British Journal of Ophthalmology.<br />
99(3):391-5, 2015 Mar<br />
Review: This prospective randomised<br />
study compared the visual<br />
performances and patient satisfaction<br />
of conventional monovision (correcting<br />
the dominant eye for distance), and<br />
crossed monovision (correcting the<br />
non-dominant eye for distance) in<br />
patients with pseudophakia. Twentyeight<br />
patients underwent bilateral<br />
cataract surgery with conventional<br />
monovision, and 31 patients with<br />
crossed monovision. The mean<br />
post-operative spherical errors in the<br />
conventional group were -0.085D<br />
(distance eye) and -1.433D (near eye),<br />
and in the crossed group -0.109D<br />
(distance eye) and -1.560D (near<br />
eye). At two months post-operatively,<br />
binocular uncorrected distance<br />
visual acuity of 20/25 or better was<br />
achieved in 89.3% of the conventional<br />
monovision group, and 83.9% of<br />
the crossed monovision group.<br />
Binocular uncorrected near visual<br />
acuity was at least 20/32 in 71.4% of<br />
the conventional group, and 67.7%<br />
of the crossed monovision group.<br />
There was no statistical difference<br />
between the two groups with regards<br />
to binocular visual acuity. A patient<br />
satisfaction survey indicated there was<br />
no significant difference in patient<br />
satisfaction for unaided binocular<br />
distance and near vision between<br />
the conventional and crossed groups.<br />
Distance glasses independence was<br />
reported by 67.9% of the conventional<br />
group, and 80.6% of the crossed<br />
group. Near glasses independence was<br />
reported by 50.0% of the conventional<br />
group, and 77.4% of the crossed group.<br />
There was no statistical difference<br />
between the two groups. Near<br />
stereopsis improved post-operatively<br />
and there was no statistical difference<br />
between the two groups.<br />
Comment: This study gives reassurance<br />
that monovision can still be considered<br />
in patients who attend for second eye<br />
surgery, when the first eye has already<br />
been operated on and corrected for<br />
distance vision, irrespective of which is<br />
the dominant eye. ▀<br />
* Dr Sue Ormonde is a<br />
consultant ophthalmologist<br />
specialising in refractive,<br />
corneal, cataract and anterior<br />
segment surgery. She works<br />
at Greenlane Hospital,<br />
Auckland and in private<br />
practice at Auckland Eye.<br />
Giving sight a sporting chance<br />
How one optometrist is<br />
helping New Zealand athletes<br />
up their game.<br />
BY JAI BREITNAUER<br />
When Wellington-based<br />
optometrist Renee Edgar<br />
was in her final year at<br />
University she completed a research<br />
project looking at the moving visual<br />
acuity of cricket players. At the time it<br />
seemed like a novel topic to complete<br />
her degree, but 13-years-later it has<br />
become a legacy project that is shaping<br />
her career.<br />
“I’ve always been interested in the<br />
relationship between vision and sport,”<br />
says Edgar. “I’m quite sporty myself and<br />
have always wondered why we don’t do<br />
different types of eye-testing for athletes.<br />
The demands on their eyes are so<br />
different to the majority of my patients<br />
in the CBD who are very static and spend<br />
most of the day in front of a computer.”<br />
Edgar notes that sports people,<br />
especially those involved in ball sports,<br />
are working daily with a moving target<br />
and have to make quick, split second<br />
decisions while that target is in motion.<br />
“It’s a lot to do with the brain as<br />
well as the eye,” says Edgar. “Eye-hand<br />
coordination develops at an early age and<br />
doesn’t always develop effectively. But<br />
those visual pathways can be re-trained.”<br />
Until recently, this interest had<br />
remained a sideline in Edgar’s work. Then<br />
she had a patient referred to her who<br />
wanted to improve his cricket game.<br />
“He was an under-16 player wanting<br />
to move up to the next level and his<br />
optometrist knew this was an area of<br />
interest for me,” says Edgar. “We began<br />
working together to improve his visual<br />
acuity. This sort of training can be very<br />
helpful for players looking to move to<br />
an elite level as it helps them perform<br />
Alcon business as usual in ANZ<br />
Despite<br />
the flurry<br />
of news<br />
this year on<br />
Novartis’ moves<br />
to turnaround its<br />
Alcon business,<br />
little is expected<br />
to change in<br />
Australasia.<br />
In response to questions from NZ<br />
Luxin Wang, general<br />
manager, Alcon ANZ<br />
Optics, Luxin Wang, general manager of<br />
Alcon Australia and New Zealand (ANZ),<br />
said Novartis’ decision to move its<br />
ophthalmic pharmaceuticals business<br />
to its wider pharmaceuticals division,<br />
allowing the Alcon division to focus<br />
solely on the surgical and vision care<br />
businesses, will have little impact here.<br />
“Our customers should see no change<br />
in our daily interactions. We have the<br />
same team in place in New Zealand<br />
who will continue to support our New<br />
Zealand customers.”<br />
Neither the Surgical business structure<br />
nor the vision care business structure will<br />
change in ANZ, said Wang. “There are no<br />
plans to change this structure although<br />
there has been a decision to combine<br />
Alcon’s ophthalmic pharmaceuticals with<br />
our parent company’s Novartis pharma<br />
Retina franchise to create a Novartis<br />
ophthalmic franchise. This will create a<br />
broad portfolio of ophthalmic medicines<br />
that treat both the front and back of the<br />
eye.”<br />
Recognising surgical and consumer<br />
require specialised expertise, Wang<br />
assured customers the plan is to<br />
continue to have two teams, one for the<br />
consumer business, for vision care and<br />
OTC pharmaceuticals, and another for<br />
surgical.<br />
Contrary to what may be happening<br />
further afield, ANZ customers can<br />
expect to see more investment from<br />
Renee Edgar and Firebirds’ Luke Woodcock, Michael Papps and Jeetan Patel<br />
at the best of their ability the majority<br />
of the time.”<br />
Mentioning this work in conversation<br />
with the mother of another patient<br />
lead to a further project for Edgar.<br />
“It turned out the lady in question<br />
was a netball umpire. She was very<br />
interested in what I was doing with the<br />
cricketer and wondered if I could help<br />
her and her colleagues as well.”<br />
However, it was when the brother of<br />
Firebirds’ coach Bruce Edgar (no relation)<br />
came in for an appointment that the<br />
project really gained momentum.<br />
“I had some information up on the<br />
wall about my work,” says Edgar. “He<br />
was very interested and got his brother<br />
to give me a call.”<br />
That was last spring, and as the<br />
cricket season had already started<br />
there wasn’t much work Edgar could<br />
do with the team, but now the season<br />
has closed for the winter the players are<br />
undergoing assessments with Edgar to<br />
see what areas need work.<br />
“So far we’ve undertaken some baseline<br />
testing to see where improvements<br />
can be made. We have concentrated<br />
very closely on spatial awareness and I<br />
have created some activities to improve<br />
the players’ perception of a moving<br />
target in space.”<br />
One such activity involves a player<br />
Alcon in both Australia and New<br />
Zealand, said Wang. “We will also<br />
continue to bring true innovation to the<br />
market and have several new product<br />
launches planned for <strong>2016</strong>.”<br />
Alcon invests in AIOL technology<br />
In other news, Alcon head office<br />
announced it had entered into a<br />
strategic alliance with PowerVision a<br />
privately-held, US-based medical device<br />
company focused on developing fluidbased<br />
lens implants.<br />
PowerVision, has developed an<br />
accommodating IOL (AIOL) for cataract<br />
patients with presbyopia, which, in pilot<br />
studies, has been shown to be able to<br />
change focus via a fluid-driven shapechanging<br />
technology, said Michael<br />
Onuscheck, global surgical franchise<br />
head for Alcon in a statement. “The<br />
technology utilises the eye’s natural<br />
accommodating muscles to transport<br />
fluid in the intraocular lens which is<br />
implanted in the eye’s capsular bag. The<br />
fluid-based technology that PowerVision<br />
is working on represents a potential<br />
game-changer in the category with<br />
the promise to offer patients a natural,<br />
continuous range of near to far vision.”<br />
Alcon’s investment in PowerVision will<br />
fund further development and clinical<br />
trials and provides Alcon with an option<br />
to acquire the company at a later stage.<br />
Alcon NZ appointment<br />
Alcon announced that Tristan Tuhi has<br />
joined its New<br />
Zealand surgical<br />
sales team as<br />
surgical account<br />
manager.<br />
“Tristan comes<br />
to us after five<br />
Tristan Tuhi<br />
years with Covidien<br />
reading a heart chart on the wall<br />
in time to a metronome, while also<br />
keeping time with flashing lights in the<br />
periphery of their vision working on a<br />
different rhythm.<br />
“It’s actually really hard,” laughs<br />
Edgar. “But these are exactly the sorts<br />
of exercises players in teams overseas<br />
regularly do. In the US, for example,<br />
it’s usual for basketball teams to have<br />
an optometrist work with the players,<br />
attending to their visual needs. I’ve<br />
thought we should offer this service for<br />
a while.”<br />
Edgar had an updated version of her<br />
university research paper published<br />
last year in the American journal,<br />
Optometry and Visual Performance,<br />
and has gained a number of clients in<br />
this area, including a golfer keen to<br />
improve his putting technique.<br />
“There are so many situations these<br />
improvement techniques could apply<br />
to,” says Edgar, who is pleased interest<br />
is gaining momentum.<br />
“It’s always been a goal for me to<br />
take this sort of work to the next level<br />
– it’s so useful and done really well<br />
overseas. I enjoy my day-to-day work<br />
as an optometrist, but this is another<br />
way of doing things a bit differently.<br />
It certainly makes my day more<br />
interesting!” ▀<br />
covering respiratory and advanced<br />
monitoring with a focus anaesthesia,”<br />
said Greg Engelbrecht, Alcon’s surgical<br />
sales manager for New Zealand. “He<br />
brings a wealth of knowledge to Alcon.”<br />
Tuhi has a BSc in physical education/<br />
health and a Diploma in Business and<br />
will be based. ▀<br />
Crosslinking<br />
advances<br />
Researchers have developed a<br />
new light-based procedure that<br />
could reduce the risk of cornea<br />
damage in crosslinking. Currently<br />
ultraviolet light is used to perform<br />
crosslinking across the entire cornea,<br />
said research leader Seok-Hyun<br />
Yun from Massachusetts General<br />
Hospital’s Wellman Center for<br />
Photomedicine in the US. “However,<br />
this comes with a risk of damaging<br />
the innermost layer of the cornea,<br />
a complication that changes the<br />
corneal function and can cause it to<br />
become very hazy.” The study focused<br />
on whether two-photon absorption<br />
could be used to precisely control<br />
the area of corneal crosslinking -<br />
an approach that has been used<br />
to harden liquid resins to create<br />
microscopic optical components and<br />
other 3D structures, but until now<br />
has not been applied to stiffen tissue.<br />
Researchers found that exposing the<br />
tissue to 200-milliwatt laser light<br />
for ten minutes induced collagen<br />
crosslinking without damaging tissue,<br />
but said more research is needed. ▀<br />
12 NEW ZEALAND OPTICS <strong>Jun</strong>e <strong>2016</strong>
Glaucoma: from<br />
Moorfields to NZ<br />
BY DR SHENTON CHEW*<br />
ANZ Strabismus Society report<br />
ANZSS Keynotes Drs Fiona Rowe and David Guyton<br />
The Australian and New Zealand Strabismus<br />
Society (aka “Squint Club”) entered its 25th<br />
year following the annual scientific meeting<br />
at the Royal Children’s Hospital in Melbourne<br />
from 4 to 6 March this year.<br />
The guest speakers at this year’s meeting<br />
were Dr David Guyton, professor of paediatric<br />
ophthalmology at John Hopkins Medicine in<br />
Balitmore, USA; and Dr Fiona Rowe, a senior<br />
lecturer in orthoptics at the University of<br />
Liverpool, a research fellow for the British and<br />
Irish Orthoptic Society and associate-editor-inchief<br />
for the journal Strabismus.<br />
Both speakers contributed greatly to the success<br />
of the meeting, which attracted 120 registrants,<br />
with a highlight being the patient presentations<br />
and discussions from Dr Guyton’s Gillies Lecture:<br />
Changes in strabismus over time: clinical<br />
implications for the future.<br />
Fiona Gillies presented the certificate of<br />
appreciate to Dr Guyton and commented on<br />
how pleased her father, Bill, would be with the<br />
enduring strength of the strabismus meeting.<br />
The meeting concluded with a Nystagmus<br />
Workshop on Sunday morning attended by<br />
35 people.<br />
Next year’s meeting will be in Auckland with guest<br />
speakers: University of Toronto Professor Stephen<br />
Kraft, staff ophthalmologist at The Hospital for Sick<br />
Children and Toronto Western Hospital; and Kyle<br />
Arnoldi, clinical instructor in ophthalmology at the<br />
Jacobs School of Medicine and Biomedical Sciences<br />
at the University of Buffalo in New York. ▀<br />
Edited from an original article supplied by the ANZSS<br />
New app for CooperVision<br />
Dr Shenton Chew (right) enjoying a beer with colleagues in a London pub next to Moorfields<br />
Travelling to the opposite end of the earth is<br />
an experience many Kiwis cherish as part<br />
of their big “OE”, and for good reason—<br />
pounds, pints and plentiful European destinations<br />
at your doorstep. Unfortunately, for those of us<br />
in the ophthalmic and optometric fields, this has<br />
been getting more difficult with strict regulations<br />
for both visas and professional qualification<br />
equivalency.<br />
One such route available to me was a twoyear,<br />
London-based glaucoma fellowship at the<br />
prestigious Moorfields Eye Hospital. I had a truly<br />
fantastic time away, soaking up not just the sights<br />
and sounds of London and its surrounds, but also<br />
the collective wisdom from some of the giants of<br />
the glaucoma world, such as Mr Keith “Mr Tube”<br />
Barton, Professor Paul “I am angle closure” Foster<br />
and the knight of the realm himself, Professor Sir<br />
Peng Khaw.<br />
Moorfields was a great blend of tradition and<br />
innovation and my hopes of being comprehensively<br />
trained in the management of complex surgical<br />
glaucoma mingled nicely with cutting-edge<br />
experience in the wide gamut of minimally<br />
invasive devices such as the iStent, Hydrus, Aquesys<br />
and Cypass, the latter two of which are not<br />
currently available in Australasia.<br />
Glaucoma is a challenging specialty. We are often<br />
faced with the difficult task of convincing a patient<br />
who has no symptomatic concerns that firstly, they<br />
have irreversible vision loss and secondly, adherence<br />
to eyedrops, which have a significant side-effect<br />
profile, is essential in preventing progression. It can<br />
be a hard sell, especially when you know that you<br />
may have 100 more patients in the waiting room, as<br />
was often the case in a busy Moorfields glaucoma<br />
clinic. Add to that, increasing demand from an aging<br />
population with increased life-expectancy and you<br />
can see why glaucoma services throughout the<br />
world are struggling to keep afloat.<br />
Fancy surgical techniques aside, efficient service<br />
provision was another aspect I hoped to glean<br />
some insight into from the largest glaucoma<br />
service in the UK. Unfortunately, Moorfields also<br />
appeared to be struggling with the burden, with<br />
obvious difficulties in seeing patients at their<br />
requested follow-up times leading to over-booked<br />
and over-running clinics, which had a significant<br />
effect on staff and patient morale. As a fellow, it<br />
was easy to suck up the workload and experience<br />
that came with it for a couple of years, but<br />
imagine a lifetime in this system and it becomes<br />
obvious as to why the poor working conditions<br />
within the British NHS (National Health Service)<br />
feature as a common news headline.<br />
Increasing staffing within the current clinic<br />
structure was the obvious initial choice to stem<br />
the overflow, given the physical space that<br />
Moorfields has. Picture a throng of patients in a<br />
large waiting area, with a large clinic area broken<br />
into eight or more cubicles, with dividers, but no<br />
walls or doors, and you have a typical Moorfields<br />
clinic. The incredible lack of privacy was an issue<br />
that patients were surprisingly accustomed to,<br />
and it did allow for rapid consultation between<br />
a variety of clinicians that manned the clinic<br />
including a consultant, a couple of fellows,<br />
a registrar, a staff specialist and a couple of<br />
optometrists.<br />
Technician-led virtual clinics were used for both<br />
stable monitoring and for new patient assessment.<br />
These certainly have scope as the use of visual field<br />
analysers and optical coherence tomography can<br />
occur on no-consultant-led glaucoma clinics days. A<br />
higher number of patients can then be “seen” by the<br />
consultant in a reporting session. As a safeguard,<br />
every patient is assessed back in the consultant<br />
clinic every three years.<br />
One would think that patient satisfaction<br />
would be lower with this style, but the analysed<br />
Moorfields’ data suggests satisfaction levels were<br />
high, perhaps due to factors such as decreased<br />
journey time and being assessed in a timely fashion.<br />
Collaborative care models have also been<br />
established with motivated community-based<br />
optometrists. Because of the wide range of<br />
optometric practices in London, those optometrists<br />
who were involved tended to have worked, or still<br />
worked, within the Moorfields glaucoma service<br />
and thus already had close relationships with their<br />
ophthalmic colleagues. This allowed them to feel<br />
confident in their own abilities and limitations,<br />
knowing that support was easy to access if required.<br />
In terms of translation to glaucoma service<br />
provision here in New Zealand, I feel a key concept<br />
is first to stratify patients by risk of visual loss.<br />
For example, a patient with early glaucoma in<br />
their 90s is unlikely to progress to functionally<br />
significant levels in their lifetime. Whereas a patient<br />
with advanced glaucoma in their 40s is going to<br />
be a challenge to keep sighted throughout their<br />
remaining years.<br />
This stratification will allow for the appropriate<br />
delivery of care. In the hospital setting, lower<br />
risk patients could funnel into a larger volume<br />
“Moorfields-style” multi-clinician clinic, while higher<br />
risk patients could feed into a smaller, ophthalmicstaffed<br />
clinic as these patients have a higher<br />
chance of needing more time for counselling and<br />
management decisions. In areas where staffing<br />
and physical space is more limited, the lower risk<br />
cohort could be reviewed through a technician-led<br />
stable monitoring service, which is what I am in the<br />
process of setting up at Waitakere Hospital, where I<br />
spend part of my clinical time.<br />
Finally, we are fortunate in New Zealand<br />
to have high quality optometrists who value<br />
eye health as a priority and a have both the<br />
knowledge-base and skill set to be invaluable<br />
in sharing this burden of glaucoma care. In fact,<br />
we ophthalmologists already rely on this with<br />
the large number of low-risk glaucoma suspects<br />
we discharge back to optometric care. Thus<br />
establishing clear lines of communication and<br />
management pathways in collaborative-care<br />
models seems like a highly successful strategy<br />
and something Moorfields, perhaps, could one<br />
day learn from us. ▀<br />
* Dr Shenton Chew is currently working with the Eye Clinic at<br />
Greenlane Clinical Centre in Auckland<br />
CooperVision has launched an app to assist<br />
optometrists in fitting toric and multifocal<br />
lenses. The free OptiExpert app with<br />
multifocal and toric calculators is available to<br />
download for iOS and Android devices and provides<br />
diagnostic lens suggestions from CooperVision’s<br />
product families: Avaira, Biofinity, Biomedics, clariti<br />
and Proclear<br />
For toric lens choices, as well as the patient’s<br />
prescription, OptiExpert considers back vertex<br />
distance adjustment and on-eye orientation, says<br />
the marketing material, plus the app converts the<br />
Efron Grading Scales into an easy-to-use digital<br />
tool, allowing practitioners to grade patients<br />
against 16 sets of images and covers the key<br />
anterior ocular complications of contact lens<br />
wear. The app also includes the ability to securely<br />
store images of the patient’s eye condition and for<br />
practitioners to add their own comments.<br />
Commenting on the expansion, Joe Tanner,<br />
SHAMIR GLACIER<br />
PREMIUM UV COATINGS<br />
FROM SHAMIR<br />
Visit us at<br />
shamir.co.nz<br />
For more information contact<br />
DONALD CRICHTON<br />
New Zealand Sales Rep<br />
021 449 819<br />
Coopervision ANZ’s<br />
professional services manager,<br />
said: “When we launched the<br />
app we made a promise to<br />
deliver a truly multi-functional<br />
digital pocket tool and this<br />
demonstrates our continued<br />
commitment to support the<br />
eye care professional who<br />
wants to make the initial<br />
diagnostic lens selection<br />
process as comprehensive as<br />
possible.”<br />
• In other news CooperVision announced it had<br />
launched Biofinity XR toric, to its Biofinity range of<br />
monthly silicone hydrogel contact lenses. Biofinity<br />
XR toric extends the high oxygen and advanced<br />
comfort of the range to patients who have both high<br />
prescriptions and astigmatism, said the company in<br />
a statement. ▀<br />
Shamir quarter page ad NZ OPTICS JUNE <strong>2016</strong>.indd 1<br />
<strong>Jun</strong>e <strong>2016</strong><br />
11/05/<strong>2016</strong> 3:58:08 PM<br />
NEW ZEALAND OPTICS<br />
13
Fresh eyes on fashion<br />
It’s the middle of the year and a perfect time to review what’s new in the style stakes with a number of high-profile new frame launches.<br />
TAVAT EYEWEAR COMES TO NZ<br />
interested in design, purpose and functionality.<br />
TAVAT’s latest launch is its “Soupcan” collection,<br />
inspired by the crude googles worn by a group of<br />
crop sprayers in Arizona, back in the ‘30s, who got<br />
together on weekends to give air-shows and called<br />
themselves, “The Flying Burritos”.<br />
A particular feature of the optical and sunglass<br />
ranges is the ex-cam hinge, a highly-engineered<br />
concept producing a fluid motion from opening<br />
to closing.<br />
SILHOUETTE WINS RED DOT<br />
Silhouette’s new Titan Minimal Art (TMA) Pulse<br />
collection has won a Red Dot Design award—the<br />
eighth award TMA has received since its launch<br />
in 1999.<br />
They’re handmade in Italy and, although titanium<br />
is a difficult product to work with, the frames are<br />
of the absolute highest quality.”<br />
Blackfin frames weigh about 10g each, yet they<br />
are exceptionally strong, with both classic and<br />
modern designs appealing to a variety of age<br />
groups and styles.<br />
“Key West is the most popular, but we stock 30<br />
styles and they’re all in demand,” says van der Maas.<br />
New additions to the range this month are<br />
Amelie and Norman. Amelie offers a modern take<br />
on the vintage cat-eye style, with clean, angular<br />
lines and a metallic colour palette. Norman has<br />
a similar, heavy-set brow, but with squared-off<br />
corners and a broader temple-line.<br />
INNOTEC INTRODUCES THE FUTURE<br />
Innotec by Ogi has announced two original<br />
styles—Emery and Ward—joining its collection of<br />
eyewear. These futuristic frames are handcrafted<br />
from TR-90 surgical-grade plastic and ultem—<br />
ground-breaking materials in the optical industry<br />
that set records for strength and weight.<br />
TAVAT now available in NZ<br />
Beni Vision in Palmerston North has added another<br />
Italian brand, TAVAT Eyewear, to its range of quality<br />
frames, which include the award-winning brand<br />
FEB31st wooden, and Blackfin titanium frames (see<br />
other story for Blackfin’s news).<br />
Dennis van der Maas, sales director for Beni Vision,<br />
says TAVAT Eyewear compliments the company’s<br />
existing product range and meets its goal of<br />
providing high quality, innovative, handmade<br />
eyewear with unique points of difference. “Having<br />
four complimenting materials, wood, titanium and<br />
now surgical stainless steel and acetate means we<br />
can now offer our customers the very best in Italian<br />
design, materials and construction.”<br />
Launched in 2010, TAVAT’s creative heart is the<br />
hills of Pasadena, California, though the frames<br />
are crafted in Northern Italy. According to the<br />
company, TAVAT offers functional iconic eyewear<br />
with real performance benefits for those in search of<br />
modernity, excellence and refined elegance and are<br />
The 4 days of Optics<br />
23 - 26 September <strong>2016</strong><br />
Sihouette’s TMA Pulse range awarded a Red Dot<br />
Weighing a mere 1.8g, with no rims, screws or<br />
hinges, TMA Pulse celebrates the sale of more than<br />
10 million items of TMA eyewear worldwide, said<br />
Silhouette the Austrian, family-owned business,<br />
which prides itself on producing super-lightweight<br />
quality eyewear. “With colour highlights on their<br />
Silhouette caps and glass fixtures in 12 fresh colours,<br />
not to mention the 12 lens shapes, this collection<br />
brings radiance to every face.”<br />
Over 5,200 products, from 57 countries, were<br />
considered by the jury for this year’s Red Dot<br />
awards. Criteria included, but were not limited to:<br />
degree of innovation, formal quality, functionality<br />
and longevity of the product. The German-based,<br />
international Product Design competition has<br />
existed since 1954. Its award, the Red Dot, is an<br />
internationally recognised quality seal.<br />
Silhouette is distributed by Elegance in Eyewear in<br />
New Zealand.<br />
BLACKFIN’S POPULARITY GROWS<br />
Since Beni Vision began stocking Blackfin frames 10<br />
months ago the company has seen a huge increase<br />
in demand based on word-of-mouth.<br />
Ward, the new style from Innotec by Ogi<br />
The Emery is a classic rectangular shape,<br />
handmade from TR-90 surgical plastic and<br />
ultem, an ultra-lightweight and flexible plastic<br />
with applications in aerospace. Equipped with<br />
metal hinge pieces and adjustable nose pads,<br />
it is comfortable and reliable, according to a<br />
statement by Ogi.<br />
Innotec’s Ward design offers an innovative keyhole<br />
bridge and is also handcrafted from TR-90 surgical<br />
plastic and ultem, with adjustable nose pads.<br />
Both styles have four different burnished colour<br />
options, and are distributed in New Zealand by BTP<br />
International Designz.<br />
WOOW! DRESSING UP URBAN STYLE<br />
WOOW partners with clothing line Le Bijou Parisien<br />
Blackfin sunglasses are stocked by Beni Vision<br />
“I have about 15 practices ordering weekly,”<br />
says Beni Vision’s Dennis van der Maas. “The<br />
construction of these frames is impeccable.<br />
WOOW eyewear have teamed up with clothing<br />
line Le Bijou Parisien for a series of photoshoots<br />
marrying together urban chic and classic style.<br />
WOOW sunglasses are handmade to a high<br />
standard while offering a modern street style that<br />
is proving to be popular with all ages. WOOW is<br />
distributed for Eyes Right Optical (NZ) by CMI Optical<br />
in New Zealand. ▀<br />
Building awareness for MD<br />
LIVE THE EXPERIENCE<br />
silmoparis.com<br />
Macular Degeneration New Zealand<br />
(MDNZ) once again invited our<br />
ophthalmic community to support<br />
the MD Awareness week at the end of May with<br />
local visibility activities.<br />
Many responded with positive actions,<br />
including displays in practices, Facebook activity<br />
and encouraging local media coverage. The<br />
<strong>2016</strong> week featured a significant social media<br />
campaign as there are 631,000 New Zealanders<br />
over 60 years of age who use Facebook. Four<br />
large billboards were displayed in Auckland, a<br />
double-page feature published in the NZ Listener,<br />
and local stories published in local media around<br />
the country. There was even full page published<br />
on MD in the<br />
Mad Butcher<br />
Newsletter.<br />
Ooh Media<br />
continue to<br />
sponsor MDNZ<br />
with the digital<br />
display signage<br />
in shopping<br />
malls across New<br />
Zealand and optometrists based in the malls<br />
were invited to capitalise on this.<br />
The consistent call to action is to save sight with<br />
the Amsler grid and for people to have their eyes<br />
tested at least once every two years. ▀<br />
14 NEW ZEALAND OPTICS <strong>Jun</strong>e <strong>2016</strong>
ACO accredited<br />
Jolanda de Jong, ACO’s head of professional development<br />
The Australian College of Optometry<br />
(ACO) has gained accreditation<br />
for CPD points in New Zealand<br />
for its online webinars and seminars,<br />
Therapeutics Refresher Weekend,<br />
Glaucoma (Diagnostic Skills) Course and<br />
its clinical workshops on BIO, Gonioscopy<br />
and OCT.<br />
Given this success, it will also be applying<br />
for accreditation for New Zealand attendees<br />
to its ACO National Conference, which will be<br />
held in Melbourne from the 22-23 October,<br />
once the programme has been finalised, said<br />
Jolanda de Jong, ACO’s general manager,<br />
professional development.<br />
“This year is the first year that we have<br />
asked for accreditation for our events in New<br />
Zealand. The ACO has provided professional<br />
development for Australian optometrists<br />
since 1975. We are very proud of our track<br />
record in this field and are delighted that we<br />
have an increasing number of New Zealand<br />
optometrists interested in joining the ACO<br />
as members take up the benefits offered by<br />
our growing number of events, either online<br />
or in person.”<br />
The time was right to apply, given the<br />
increasing ease and familiarity with online<br />
certificate courses, says de Jong. “The<br />
ACO now offers a very comprehensive<br />
CPD programme and the fact that these<br />
activities are now accredited in New Zealand<br />
offers an expanded suite of options to New<br />
Zealand optometrists. Overall we see this<br />
as a great opportunity to share knowledge,<br />
present diverse speakers, broaden networks<br />
and strengthen the relationship between<br />
colleagues in both countries. Learning<br />
together is a positive step forward for the<br />
profession as a whole.” ▀<br />
Reflections on long careers<br />
Mike Firmston and Bryan<br />
Matthews take time out to<br />
reflect on a combined 100<br />
plus years in business with<br />
NZ Optics’ editor-at-large<br />
Maryanne Dransfield<br />
After 46 and 55 years in the<br />
optical business, respectively,<br />
Mike Firmston and Bryan<br />
Matthews have sold their “retirement”<br />
practice, Specs Direct.<br />
“It was the right time to go.<br />
Optometrist Donald Klaassen who has worked for us for many years<br />
was interested in buying the practice so it made the decision a little<br />
easier to make,” said Mike.<br />
Bryan and Mike were responsible for changing the face of retail<br />
optics in New Zealand when they opened the Optique Boutique chain<br />
of stores in the mid-80s.<br />
“I guess we were at the cutting edge of the change that started in the<br />
mid-80s. The retail appearance we presented in Optique Boutique was<br />
revolutionary for the time and changed the way DO’s and optometrists<br />
thought about how they marketed themselves and their services to<br />
the public,” said Bryan.<br />
The opening of the stores was like a rollercoaster ride, they both<br />
added. The first to open was in Sandringham, followed closely by<br />
Symonds Street and then High Street in central Auckland.<br />
“The public was ready for a new approach in buying their glasses.<br />
Licenses on spectacles had been removed and as a result there was a<br />
tsunami of agencies and brands available to us. It was very exciting<br />
times,” said Mike.<br />
The wholesale and manufacturing arm of the company, Bryan<br />
Matthews Optical, established in 1970, was supplying its own stores<br />
as well as other practices. Originally owned by Bryan and his brother<br />
Craig, brother-in-law Mike joined them in 1973 on his return to New<br />
Zealand from working overseas. Mike brought with him experience in<br />
management and accounting, enabling the Matthews to develop their<br />
business further. Dennis Irvine also joined them at this time to assist<br />
with the opening of the stores.<br />
Optique Boutique underwent a name change once the stores opened<br />
in malls in Auckland and Chartwell in Hamilton, becoming known as<br />
Optique Eyewear. In 1995 the chain of eight stores was sold to OPSM<br />
giving the Australian company a foothold in the New Zealand market.<br />
For Mike, the next five years were spent as New Zealand<br />
administration manager for OPSM, while Bryan continued with<br />
Tranzoptics, the wholesale successor to Bryan Matthews Optical.<br />
Then, in <strong>Jun</strong>e 2000, Mike and Bryan joined forces again in a new<br />
business venture, Specs Direct. The first, factory-type outlet was<br />
in Sandringham and another in Albany soon followed. A semiretirement<br />
venture, the philosophy behind the business was<br />
that product was to be priced to the overheads, which were low<br />
compared to retail practices.<br />
“At the time there was a definite public perception that<br />
prescription glasses were too expensive and until then there<br />
had been nowhere people could go except The Warehouse and<br />
pharmacies to purchase ready-readers. We decided to fill that market<br />
gap,” Mike said.<br />
Bryan has an extensive background in the industry and is probably<br />
the only person in New Zealand who has been involved in the<br />
production of lenses, frame making, dispensing and retail. His<br />
career began in 1960 at Standard Optical in Auckland before moving<br />
to Arthur Cocks in 1963, where he also worked with lenses. Two<br />
years later he joined Owen Optical to work for a year with Robert<br />
Leitl training in the frame-making process, before moving on to<br />
overseeing frame production. In 1974 he left to establish his own<br />
frame making company, but market forces came into play prohibiting<br />
him from gaining a license to obtain the materials necessary to<br />
manufacture frames. Whilst continuing to lobby for a license, Bryan<br />
began dispensing from these premises gaining a lot of referrals from<br />
ophthalmologists. It was around this time he formed a business<br />
relationship with Harold Searle who established Reads Optical and<br />
Press clipping of Mike and Bryan at their Balmoral shop in the mid 70’s<br />
Brian Matthews Optical in the ‘80s<br />
Mike Firmston and Bryan Matthews today<br />
with whom he would place his lens business for the next 40 years.<br />
“When no-one else would handle our lens business, Harold was the<br />
only one. I was very grateful to him. Of course it was a different story<br />
when we setup our chain of stores, I had everyone knocking on my<br />
door.”<br />
By 1975, Bryan Matthews Optical gained its frame license. It<br />
manufactured frames for their own outlets as well as selling to<br />
optometrists once they gained some big-brand agencies. The company<br />
was the first in the country to obtain a license for CR39 lenses, much to<br />
the dismay of other labs.<br />
“Once Optique Boutique opened, a lot of practices did not like the<br />
fact that we were retailing as well so they wouldn’t buy from us…we<br />
were so busy with our retail operation it suited us to wind down the<br />
wholesaling side,” said Bryan.<br />
Bryan was able to dispense as he got in under the “grandfather<br />
clause,” but Mike decided to do the dispensing opticians course,<br />
qualifying in 1980. He joined what was then known as Dispensing<br />
Opticians of New Zealand (now ADONZ) and worked tirelessly<br />
serving in a variety of roles for the organisation over the next<br />
three and half decades. He was elected to the Opticians’ Board<br />
(now ODOB) in 2001 serving for nine years. He helped establish,<br />
and is still a director of, OptiBlocks, the educational course for<br />
trainee dispensers.<br />
Mike was awarded the Robert Maher Award in 2010, recognising<br />
his significant contribution to the industry, and life membership<br />
of ADONZ in 2012. He was also awarded the prestigious Essilor<br />
scholarship to the Varilux Academy, which he took in 2009.<br />
One of the highlights of Mike’s career in optics has been the<br />
camaraderie and professionalism among the people in the industry, he<br />
said. “I have enjoyed the interaction with everyone I have encountered<br />
over the years…and I have made many lifelong friends. It’s been an<br />
incredible industry to work in and I feel privileged to have made links<br />
with people worldwide and to have had the opportunity to understand<br />
the different perspectives people have. I’ve seen many changes, but<br />
most of all it’s been great to see how our Association (ADONZ) has<br />
developed to what it is today.”<br />
Bryan said the last 56 years has been one big journey with many<br />
ups and downs. “We were successful because we trusted each other.<br />
We were a great combination - Mike is a people’s person, Craig was<br />
highly efficient in the area of technology. We would have been the first<br />
wholesaler in New Zealand to have run a computerised system, while<br />
my travelling gave me insights into trends and what was the next big<br />
thing in eyewear, which always kept us ahead of the competition.”<br />
Asked about his plans for retirement, Bryan said optics is still very<br />
WAVE <strong>2016</strong><br />
western australian<br />
vision education<br />
workshop in the west<br />
Saturday & Sunday 13-14 August <strong>2016</strong><br />
UP TO<br />
46<br />
Magazine advert 9x35.5cm.indd 1<br />
EArly bird HUGE SAViNGS<br />
rEGiSTEr<br />
NOW!<br />
Rendezvous Hotel, Perth,<br />
Western Australia<br />
www.optometry.org.au/wa<br />
UP TO<br />
31.5T<br />
29/04/<strong>2016</strong> 1:41 pm<br />
much in his blood and is planning to dabble in small-time production<br />
again with Craig. “Out of everything I’ve done over the past 56 years,<br />
the manufacturing aspect was the thing I enjoyed the most.”<br />
Mike and his wife Rae are planning a four-month overseas trip to<br />
Europe. When they return, Mike said he is looking forward to becoming<br />
a volunteer in several organisations and undertaking a massive<br />
gardening challenge with his neighbour. ▀<br />
<strong>Jun</strong>e <strong>2016</strong><br />
NEW ZEALAND OPTICS<br />
15
with<br />
Prof Charles McGhee<br />
& A/Prof Dipika Patel<br />
Series Editors<br />
Choosing topical antibiotics wisely<br />
BY JAY MEYER*<br />
There are many factors that influence the selection of an<br />
antibiotic for a given clinical scenario. Some questions that<br />
assist in the decision-making process include the following:<br />
••<br />
Is the antibiotic for prophylaxis or for treatment of infection?<br />
••<br />
If treating infection, is the causative organism known?<br />
••<br />
If the causative organism is unknown, is there a<br />
predisposition for gram positive or gram negative organisms<br />
to cause this type of infection?<br />
••<br />
Does the patient have any contraindications to antibiotics?<br />
Common situations where topical antibiotics are used<br />
for infection prophylaxis include: corneal abrasions, pre or<br />
postoperative following extraocular surgery (refractive surgery,<br />
pterygium excision, etc.) or intraocular surgery (cataract, glaucoma,<br />
or retinal surgery, etc.). Superficial ocular infections that are often<br />
bacterial include conjunctivitis and keratitis. Some “non-infectious”<br />
conditions that are often adjunctively treated with antibiotics<br />
include blepharitis and marginal keratitis. Considerations regarding<br />
some of these specific clinical conditions are presented below:<br />
Conjunctivitis. Major causes of conjunctivitis include: viral,<br />
bacterial, chlamydial, and allergic. Acute bacterial conjunctivitis<br />
is often self-limiting; however, treatment with an antibiotic may<br />
accelerate the resolution of infection. Most bacteria causing<br />
this condition in children (excluding infants) and adults are<br />
gram positive, such as Staphylococcus aureus or Streptococcus<br />
pneumoniae. A broad spectrum antibiotic with gram positive<br />
coverage such as chloramphenicol or fusidic acid would be<br />
expected to treat the infection. Ciprofloxacin has poor coverage<br />
of streptococcus and is generally reserved for use in more severe<br />
ocular infections. Clinical response is generally seen within a few<br />
days and the course continued for 5-7 days total. A conjunctival<br />
swab for bacteria, viruses (HSV, adenovirus), or chlamydia may be<br />
performed for chronic conjunctivitis or for cases where the history<br />
and exam suggest an alternative etiology or do not respond to<br />
initial antibacterial treatment.<br />
Keratitis. In New Zealand, the majority (70-80%) of bacterial<br />
keratitis isolates are gram positive organisms, most commonly<br />
coagulase negative staphylococci or Staphylococcus aureus. Of<br />
gram negative organisms, Moraxella spp. and Pseudomonas<br />
aeruginosa are the most common. Fungal and acanthamoeba<br />
keratitis rarely occur in New Zealand, and combined they represent<br />
less than 5% of isolates from severe keratitis. 1,2<br />
Standard treatment regimens for microbial keratitis are<br />
monotherapy with a fluoroquinolone, such as ciprofloxacin, or<br />
dual therapy with fortified antibiotics (usually aminoglycoside<br />
and cephalosporin). Studies have not shown a difference in the<br />
effectiveness between these two regimens. 3 Ciprofloxacin has the<br />
advantage of being a single, commercially available agent, and is<br />
generally well tolerated. In contrast, the fortified aminoglycoside/<br />
cephalosporin antibiotics have a short shelf life, require<br />
refrigeration, must be obtained from a specialised pharmacy,<br />
and may cause more surface toxicity. As a result, ciprofloxacin is<br />
frequently used to empirically treat keratitis, and a study from<br />
Waikato Hospital from 2003-2007 showed that 99% of bacterial<br />
keratitis isolates were sensitive to ciprofloxacin. 1 However, there<br />
are some reported gaps in ciprofloxacin’s coverage of gram positive<br />
organisms 4 and many clinicians treat severe, central, visionthreatening<br />
keratitis (Fig. 1) using dual therapy for additional<br />
coverage of potential organisms. Because chloramphenicol is<br />
bacteriostatic, rather than bactericidal, it is generally not used as<br />
primary treatment of severe corneal infections. The addition of<br />
an antibiotic ointment at bedtime (such as chloramphenicol or<br />
tobramycin) may augment the use of daytime eye drops.<br />
When treating a bacterial infection (conjunctivitis or keratitis),<br />
there is usually improvement (or in the case of severe keratitis, at<br />
least no worsening) within 2-3 days of treatment. If the infection<br />
is not responding, consider: incorrect diagnosis, non-compliance,<br />
subtherapeutic dosing frequency, or inappropriate choice of drug.<br />
Blepharitis. While blepharitis is not due to an infection per<br />
se, treatment with an antibiotic may be a beneficial adjunct<br />
to other treatments, particularly when due to staphylococcal<br />
hypersensitivity. Similarly, “staphylococcal” marginal keratitis<br />
(Fig. 2) is due to a hypersensitivity reaction to bacterial antigens.<br />
The acute management of marginal keratitis requires treatment<br />
with a topical corticosteroid. However, strategies to minimise the<br />
recurrence include the institution of an eyelid cleaning regimen<br />
along with a course of nightly topical antibiotic with activity<br />
against gram positive organisms. Fusidic acid has good coverage<br />
against staphylococcus and also has immunosuppressive properties<br />
which make it a useful treatment option for many patients to<br />
reduce bacterial loads and inflammation.<br />
ANTIBIOTICS<br />
An overview of the commercially available topical antibiotics is<br />
presented below. Other antibiotics may be available through special<br />
order through a compounding pharmacy and are not covered in<br />
this review. Additionally, anti-viral and anti-fungal agents have not<br />
been included.<br />
CHLORAMPHENICOL. Available as 0.5% eye drops (Chlorafast) or 1%<br />
ointment (Chlorsig).<br />
Mechanism of Action: Bacteriostatic. Inhibits protein synthesis.<br />
Spectrum of coverage: Broad, most gram positive and gram<br />
negative organisms. Not effective against Pseudomonas<br />
aeruginosa.<br />
Considerations: Aplastic anemia is a serious, life-threatening,<br />
side effect but the risk is extremely low with topical use (less<br />
than 1 in 224,716 prescriptions). 5 Other risks include gray baby<br />
syndrome, so treatment during pregnancy should be avoided<br />
during the last week before parturition and while breast-feeding.<br />
As with all medications, topical irritation/allergy can occur (Fig.<br />
3). Most commonly used to treat conjunctivitis or for prophylaxis<br />
of infection. The solution contains phenyl mercuric nitrate as a<br />
preservative, and the ointment is preservative-free, so may be used<br />
in patients with allergy to benzalkonium chloride (BAK).<br />
CIPROFLOXACIN. Available as 0.3% eye drops (Ciloxan)<br />
Mechanism of Action: Bactericidal. Interferes with DNA synthesis.<br />
Spectrum of coverage: Broad range of gram positive and gram<br />
negative organisms and very effective against pseudomonas.<br />
Considerations: May form crystalline precipitates on the ocular<br />
surface which may obscure the visualization of an ulcer base when<br />
treating keratitis.<br />
AMINOGLYCOSIDES. Gentamicin (Genoptic), Tobramycin (Tobrex)<br />
0.3% eye drops or ointment. Neomycin and Framycetin available in<br />
combination with dexamethasone.<br />
Mechanism of Action: Bactericidal (concentration dependent).<br />
Inhibits protein synthesis through binding of ribosomal subunits.<br />
Spectrum of coverage: Broad, gram negative and moderate gram<br />
positive with some resistance among Streptococcus pneumonia.<br />
Considerations: Poor ocular penetration. Among aminoglycosides,<br />
tobramycin has best activity against pseudomonas aeruginosa.<br />
Aminoglycosides may cause surface toxicity including superficial<br />
punctate keratitis and erythema/oedema of the conjunctiva, mostly<br />
after the drug is used in excess of 1-2 weeks.<br />
NEOMYCIN/POLYMIXIN B. Component of Maxitrol along with<br />
dexamethasone 0.1% as a solution or ointment.<br />
Mechanism of Action: Neomycin is an aminoglycoside and<br />
inhibits protein synthesis. Polymixin B sulfate alters bacterial cell<br />
membranes.<br />
Spectrum of coverage: Neomycin has excellent gram negative<br />
coverage with partial gram positive coverage. Polymixin B is<br />
bactericidal for gram negative with little effect on gram positive<br />
organisms.<br />
Considerations: As a combination antibiotic/steroid this is not<br />
frequently used in the treatment of infections. However, this<br />
combination is often used as postoperative prophylaxis of infection<br />
due to the convenience of a single medication. Roughly 5% of<br />
patients may experience a delayed hypersensitivity reaction to<br />
neomycin consisting of itching, erythema/oedema of the eyelids<br />
and conjunctiva, and possibly a superficial punctate keratitis.<br />
This usually occurs after several days of treatment, if previously<br />
unexposed, or within 12-72 hours if previously exposed.<br />
FRAMYCETIN/GRAMICIDIN. Component of Sofradex along with<br />
dexamethasone 0.05%.<br />
Mechanism of action: Framycetin sulfate is an aminoglycoside<br />
and inhibits protein synthesis. Gramicidin increases permeability of<br />
the bacterial cell.<br />
Spectrum of coverage: Framycetin has broad coverage with<br />
clinical use targeting gram organisims. Gramicidin is active against<br />
gram positive bacteria and reinforces the action of framycetin<br />
against streptococci.<br />
Considerations: In comparison to Maxitrol, contains a lower<br />
concentration of dexamethasone and may have greater activity<br />
against some gram positive organisms.<br />
SULFONAMIDES. Sulfacetamide sodium 10% solution (Bleph-10)<br />
Mechanism of Action: Bacteriostatic. Acts as an antimetabolite to<br />
inhibit folate metabolism.<br />
Spectrum of coverage: Inhibits gram positive and gram negative<br />
bacteria. Poor coverage of pseudomonas and significant percentage<br />
of staphylococci are resistant.<br />
Considerations: Should not be used if hypersensitivity to sulfa<br />
drugs. Rare potential side effect is Stevens-Johnson syndrome.<br />
FUSIDIC ACID. Available as 1% viscous eye drops (Fucithalmic)<br />
Mechanism of Action: Inhibits protein synthesis.<br />
Spectrum of coverage: Bacteriostatic activity against a wide range<br />
of gram positive, particularly staphylococcus.<br />
Considerations: Also has immunosuppressive properties,<br />
making it a good choice for blepharitis due to staphylococcal<br />
hypersensitivity.<br />
PROPAMIDINE. Available as (Brolene) solution or ointment without<br />
a prescription<br />
Mechanism of Action: Bacteriostatic. Causes damage to the cell<br />
surface.<br />
Spectrum of coverage: Broad spectrum antimicrobial, may have<br />
activity against antibiotic-resistant staphylococci.<br />
Considerations: This is often only prescribed by ophthalmologists<br />
for the treatment of acanthamoeba keratitis. ▀<br />
References<br />
Fig 1. Severe microbial keratitis with a large, central, elevated infiltrate due<br />
to Moraxella.<br />
Fig 2. Blepharitis and staphylococcal marginal keratitis with paralimbal<br />
corneal infiltrates from 2 to 5 o’clock.<br />
Fig 3. Severe contact dermatitis and allergic conjunctivitis due to<br />
frequent application of chloramphenicol solution.<br />
1. Pandita A, Murphy C. Microbial keratitis in Waikato, New Zealand. Clin<br />
Experiment Ophthalmol 2011;39:393–7.<br />
2. Wong T, Ormonde S, Gamble G, McGhee CNJ. Severe infective keratitis leading<br />
to hospital admission in New Zealand. Br J Ophthalmol 2003;87:1103-1108.<br />
3. McDonald EM, Ram FSF, Patel DV, McGhee CNJ. Topical antibiotics for the<br />
management of bacterial keratitis: an evidence-based review of high quality<br />
randomised controlled trials. Br J Ophthalmol 2014;98:1470-7.<br />
4. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in<br />
bacterial keratitis. Ophthalmology 1999;106:1313-8.<br />
5. Lancaster T, Stewart AM, Jick H. Risk of serious haematological toxicity with<br />
use of chloramphenicol eye drops in a British general practice database. Br<br />
Med J 1998;316:667.<br />
About the author<br />
* Jay Meyer is an anterior segment fellow at the<br />
University of Auckland and has an interest<br />
in ocular infections. Prior to his training in<br />
ophthalmology, he completed a B.S. degree<br />
in microbiology and as a medical student<br />
described a novel species of mycobacteria<br />
(Mycobacterium arupense).<br />
16 NEW ZEALAND OPTICS <strong>Jun</strong>e <strong>2016</strong>
Celebrating Bruce Hadden MD<br />
Associate Professor Bruce Hadden’s long<br />
standing support for (and association<br />
with) the Department of Ophthalmology<br />
at the University of Auckland was honoured in a<br />
celebration in April. The evening also marked<br />
A/Prof Hadden’s recent success for achieving an<br />
MD (Doctor of Medicine) by research.<br />
Professor Charles McGhee, head of the<br />
Ophthalmology Department, chaired the event,<br />
Professor Stuart McCutcheon (left) andProfessor Alan Merry (right) raise a glass to A/Prof Bruce Hadden<br />
welcoming the 50 plus guests, before sharing<br />
some amusing anecdotes about how he met<br />
Bruce (in the men’s room in Melbourne) and<br />
how he was one of five key people who were<br />
responsible for him coming to New Zealand and<br />
happily remaining here.<br />
To the continued amusement of the audience,<br />
Professor McGhee also related the tale of how he<br />
conspired with Bruce’s wife, Dr Wendy Hadden,<br />
to keep Bruce busy when he retired from a long<br />
and distinguished ophthalmological career,<br />
appointing him honorary Associate Professor in<br />
Ophthalmology. Since then Bruce has become a<br />
favourite with students as a teacher, is still the<br />
go-to person for any clinical or diplomatic advice,<br />
has published a major textbook on eye surgery<br />
and eye surgeons in New Zealand plus 30+ papers<br />
in scientific journals and completed his MD.<br />
Professor McGhee summed up Bruce as too<br />
modest. “He’s an outstanding clinician and<br />
surgeon. He and Wendy have been fantastic<br />
supporters of the department…he’s retained an<br />
intellectual curiosity through his entire career, he<br />
keeps his students sharp and on their toes…he’s<br />
an unstinting friend of the faculty, he’s always<br />
diplomatic and he’s an outstanding friend.”<br />
Professor Stuart McCutcheon, vice chancellor of<br />
the University, admitted when he was first invited<br />
to talk, he thought the function was to mark<br />
Bruce’s retirement so was pleased to find out this<br />
wasn’t so. He thanked Bruce and Wendy for their<br />
long and committed support of the Faculty and<br />
the Department, concluding his speech by saying<br />
that: “Associate Professor, Doctor, Doctor, Mr<br />
Hadden” was without doubt a great example of<br />
the best in Town and Gown.<br />
Professor Alan Merry, head of the School<br />
of Medicine, also reflected on some of the<br />
achievements of Bruce’s outstanding career,<br />
including his stint as the first New Zealand<br />
president of RANZCO, and how he has<br />
been instrumental in the development of<br />
ophthalmology in New Zealand. ▀<br />
Maree McInerney, Professor Colin Green, Dr Sue Ormonde and A/Prof<br />
Trevor Sherwin<br />
A/Prof Bruce and Dr Wendy Hadden with Suzanne Renner and A/Prof<br />
Gordon Sanderson<br />
Heather Reynolds, Cecilia Chin, A/Prof Bruce Hadden and Jasha Morarji Heather Reynolds, A/Prof Gillian Clover and Professor Charles McGhee A/Prof Bruce Hadden mingling with guests A/Prof Dipika Patel and Drs Verity Oliver, Stuti Misra and Carol Greene<br />
Education out<br />
of this world<br />
Jon Baines Tours, a specialist provider of fully escorted medical<br />
tours, is now taking bookings now for its next ophthalmology tour<br />
in Japan and optometry tour in Peru in 2017. The tours explore<br />
destinations through the eyes of a particular profession, visiting<br />
clinics, meeting specialists from those regions, while also providing<br />
a full cultural programme, covering the key sites of a country.<br />
Ophthalmology in Japan: 28 February - 11 March 2017<br />
This study tour will be led by Professor Christopher Liu, a consultant<br />
ophthalmic surgeon based in Britain. It encompasses Tokyo, the<br />
former Samurai town of Kanazawa, Osaka, Hiroshima and Kyoto and<br />
includes visits to eye hospitals and ophthalmic centres, lectures<br />
and meetings with Japanese colleagues. The wide ranging cultural<br />
programme will include museums, castles, gardens and temples as<br />
well as contemporary Japan.<br />
Optometry in Peru: 2–14 April 2017<br />
The annual optometry tour is going to Peru and will be led by regular,<br />
UK-based tour leader, optometrist David Shannon. Peru is a country as<br />
varied in culture as it is in natural landscapes. This tour will travel from<br />
the capital, Lima, to the ancient Inca capital, Cuzco, before heading<br />
to the lost city of Machu Picchu, the Andes and Lake Titicaca to visit<br />
traditional communities. It includes a range of professional visits<br />
examining emerging optometry and eyecare throughout Peru.<br />
For more about either tour visit:<br />
www.jonbainestours.co.uk/optometry. ▀<br />
Lumenis presents OPT results<br />
Lumenis, the world’s largest energy-based medical device<br />
company for aesthetic, surgical and ophthalmic applications,<br />
presented interim results of a multicentre prospective clinical<br />
trial designed to study the safety and efficacy of Optimal Pulse<br />
Technology (OPT), the next generation of Intense Pulse Light (IPL)<br />
technology, for treating dry eye disease (DED). Data from the trial, led<br />
by Steven J. Dell, MD, of Dell Laser Consultants in Austin, Texas, was<br />
presented at the ASCRS conference held May 6-10 in New Orleans.<br />
In the trial, 40 patients from two centres received three IPL with<br />
OPT treatments for DED caused by Meibomian gland dysfunction<br />
(MGD). Tear break-up time, SPEED questionnaire scores, tear<br />
osmolarity and additional endpoints were measured at baseline and<br />
again after treatment.<br />
“Many of my patients with dry eye due to MGD report significant<br />
ocular discomfort that limits their ability to work, participate in<br />
hobbies or use computers, smartphones and tablets. For these<br />
reasons, it is important that we have effective and safe treatments<br />
that help patients resume normal activities without visual<br />
symptoms,” Dr Dell said.<br />
Sheila Barbarino, MD, of Dell Laser Consultants, presented interim<br />
results of 14 patients who finished all treatments and follow-ups.<br />
“I am excited to present the data from our study,” Dr Barbarino said.<br />
“More than 40 million Americans suffer from dry eye and several<br />
studies show that MGD plays a primary role in a majority of cases.<br />
The data from our study suggests that IPL with OPT could be an<br />
important addition to our armamentarium of treatments for this<br />
prevalent, life-altering disease.”<br />
Lumenis M22 IPL with OPT is a clinically-proven and TGA and<br />
Medsafe -cleared therapy for a wide range of skin conditions,<br />
including inflammatory disorders such as rosacea. More than<br />
a decade ago, Rolando Toyos, MD, of Toyos Clinic in Nashville,<br />
Tennessee, observed that patients treated with IPL for skin conditions<br />
reported significant improvement in ocular symptoms and signs, in<br />
some cases including resolution of concomitant MGD. Studies show<br />
that over 85% of individuals with skin and eyelid inflammation also<br />
suffer from inflammatory ocular conditions, such as MGD, blepharitis<br />
and eyelid telangiectasia. IPL with OPT may selectively target<br />
abnormal blood vessels and remove a major source of inflammation<br />
from the skin and eyelids of these patients, providing symptomatic<br />
relief and addressing the underlying causative pathway of their<br />
Lumenis’ Optimal Pulse Technology in action<br />
SPONSORED FEATURE<br />
ocular disease.<br />
Lumenis OPT proprietary technology ensures the delivery of<br />
consistent and homogenous levels of energy during brief IPL pulses,<br />
thus eliminating unsafe energy spikes, increasing reproducibility and<br />
improving results with fewer treatment sessions while reducing the<br />
risk of skin damage. The results of the study have indicated a 220%<br />
improvement in tear break up time, a greater than 50% improvement<br />
in SPEED Questionnaire scores and a greater than 40% improvement<br />
in relative osmolality readings of the tear film. This demonstrates<br />
both a significant improvement in the objective markers used as<br />
well as the patients reporting significant subjective improvements.<br />
The M22 with OPT is available now from Lumenis Australia/ New<br />
Zealand. Further information or to request a demo is on the website<br />
www.lumenis.com/Solutions/Ophthalmology/Products/M22. ▀<br />
<strong>Jun</strong>e <strong>2016</strong><br />
NEW ZEALAND OPTICS<br />
17
An international query<br />
Registrations<br />
open for<br />
WAVE<br />
An international reader recently sent me the following email query:<br />
“I have a question that you have probably answered in one of your<br />
columns already - hope you don’t mind! In the toss up between dailies<br />
that are not siHy and well cared for monthlies that are siHy, would you choose<br />
the dailies still?”<br />
That’s a tough question!<br />
It certainly got me thinking as this seemingly simple question involves a<br />
great many fundamentals of contact lenses. I have dealt with many aspects of<br />
such issues in past columns but felt a review was in order as our lens options<br />
become ever wider and better, as does our understanding of such things.<br />
One such aspect obviously regards oxygen permeability and lens<br />
thickness. We’ve talked a lot in the past about Dk/L, Holden-Mertz criteria,<br />
neovascularisation, striae and the like, so I won’t repeat it here. I will, however,<br />
try and put it into a relevant and relative context.<br />
Of course it’s not as simple as merely considering SiHy versus hydrogels or<br />
oxygen transmission.<br />
Today a hydrogel daily like the biomimetic 78% water content Biotrue<br />
ONEday hydrogel provides a Dk of around 42 units. The Dk is thus not too far<br />
off the Dk of some silicone-hydrogels - on the lower end of SiHy Dk range of<br />
around the 50 unit mark. So for many patients a hydrogel like Biotrue ONEday<br />
will be pretty much the same physiologically. It may, however, have some<br />
benefits in terms of avoiding solution-lens interactions, allergies and sensitivity<br />
as well as potential benefits for the so-called and rare silicone-responders.<br />
There are also other lenses like the biocompatible and zwitterionic Proclear<br />
dailies that also have reasonably decent Dk of around 25 units. 1-Day Acuvue<br />
Moist boasts a similar Dk yet adds the benefit of high levels of UV protection<br />
that are important in climes like South Africa, Australia and New Zealand. The<br />
Focus range of dailies also have similar Dk and perform very well.<br />
I have used and continue to use and prescribe all the above lenses with<br />
excellent results over two decades on many simple and complex patients. I<br />
rarely see any complications and in fact have solved many problems in patients<br />
with Thygeson’s-like, solution-lens related keratopathy and a variety of other<br />
problems, sensitivity and complications they had with reusable lenses.<br />
Today of course we have some next generation SiHy dailies that are providing<br />
fantastic levels of comfort and masses of oxygen and today these are my first<br />
choice.<br />
Qualification<br />
Thus I qualified the email query as I suspected that the question was not<br />
purely related to which was ‘better’ and suspected that cost was the issue.<br />
They responded that was in fact the underlying reason for their question. They<br />
practise in South Africa where it seems there is a wider gap in cost between an<br />
annual supply of dailies versus monthly lenses and also a wider gap between<br />
SiHy dailies versus hydrogel dailies.<br />
To me cost is never my first consideration. In fact I rarely even discuss the<br />
cost with patients. Of course it does on occasion arise. I have also discussed<br />
this at length in my columns over the years. The way I handle the cost issue is<br />
simply to state that if we provide a bulk supply of dailies and compare that to<br />
the annual cost of two-weekly or monthly reusable lenses, PLUS the annual<br />
solution cost, then we are not talking about budget busting differences.<br />
If you add in the increased likelihood of the need for unscheduled visits,<br />
ophthalmological referral or expensive eye drops with reusable lenses then<br />
we are looking at break-even or even dailies winning the battle. As Efron has<br />
also showed dailies break even at five days of use compared to seven day use<br />
of reusable lenses. As I’ve said many times I simply tell my patients that dailies<br />
will cost them around the cost of a cappuccino per day. Many spend more than<br />
that on coffee, booze, cigarettes and beauty products so one needs to provide<br />
a relative perspective. For many the convenience of dailies outweighs any cost<br />
differential.<br />
I won’t get into the Internet debate here as that affects both dailies and reusable<br />
lenses in a similar fashion.<br />
All Things Being Equal<br />
If someone wearing say a –3.00 Acuvue/Proclear/Focus et al daily was<br />
asymptomatic, with no sign of physiological compromise and all looked good, I<br />
would rather remain in such lenses than refit a SiHy monthly. To me going from<br />
dailies to reusable is a retrograde step!<br />
I’ve spent most of the past 20 years refitting reusable lens wearers into<br />
dailies with fantastic results. I very rarely see complications. Pretty much the<br />
only issue that occasionally arises is that of reduced end-of-day comfort or<br />
tired, heavy-feeling, dry eyes. These days we solve most of those problems<br />
refitting people into the latest generation SiHy dailies like Dailies Total 1 or the<br />
fantastic new Acuvue Oasys 1 Day (AO1D).<br />
AO1D is surpassing pretty much every other lens I’ve ever prescribed in terms<br />
of comfort, vision and all day comfort.<br />
I’ll be sharing some of these cases at the Acuvue Oasys 1 Day launches that<br />
will have just been completed by the time you read this.<br />
I hope this clarifies some of the issues and considerations that this email<br />
query spurned.<br />
I always appreciate feedback from readers and am happy to consider such<br />
questions.<br />
I asked the writer of the query if my much shorter email response satisfied<br />
her query. She responded as follows;<br />
“That does!<br />
It’s just that the siHy daily is so much more expensive than a regular daily<br />
that I am often asked that question.<br />
So basically if a patient is asymptomatic any daily is better even if it’s<br />
hydrogel! As a general rule!<br />
Thanks a million.”<br />
Like I said it is hard to oversimplify things but essentially yes, a quality<br />
hydrogel daily with sufficient Dk in an asymptomatic and physiologically<br />
uncompromised patient would be my pick over a reusable lens of any material,<br />
SiHy or hydrogel. ▀<br />
* Disclosure of interest: Alan Saks was not sponsored by J&J to review Acuvue Oasys 1-Day, but was<br />
engaged by J&J to report on his findings at a series of launch meetings in Australasia in May<br />
Rendezvous Hotel Perth Scarborough: the venue for this year’s WAVE<br />
Registrations are now open for the <strong>2016</strong><br />
Western Australian Vision Education (WAVE)<br />
Conference on the 13-14 August in Perth. The<br />
conference venue is the stunning Rendezvous Hotel<br />
overlooking the white sands of Scarborough Beach.<br />
Darrell Baker, Optometry WA president, says this<br />
year’s programme will continue to deliver the high<br />
standards of clinical and professional education<br />
WAVE has become renowned for. “It will again<br />
include a group of talented presenters leading the<br />
way in new topics and ground-breaking research<br />
discoveries. We look forward to seeing you in our<br />
wonderful state, Western Australia, and to you<br />
enjoying the WAVE experience.”<br />
Programme highlights this year include the<br />
Saturday Clinical Workshops; the short, sharp and<br />
detailed, diverse Lecture Series; the CR Surfacing<br />
Saturday Evening Sundowner soiree and the trade<br />
exhibition in the hotel’s Grand Ballroom.<br />
Speakers include Margaret Lam, founder of<br />
Sydney-based theeyecarecompany, who’s wellknown<br />
for her passionate interest in all things<br />
contact lenses; Dr Lasitha Jayasinghe, a consultant<br />
ophthalmologist and former Research and<br />
Clinical Fellow in cornea, external eye diseases<br />
and refractive surgery with the Singapore Eye<br />
Research Institute and Singapore National Eye<br />
Centre; Liz Jackson, a fellow of the Australian<br />
College of Behavioural Optometry; ophthalmic<br />
medicines prescriber Stephen Leslie on some of<br />
the more complex areas of optometry including<br />
rehabilitative optometric care of acquired brain<br />
injury; and a host of others.<br />
The venue, the Rendezvous Hotel Perth<br />
Scarborough, is just a 30-minute drive from Perth<br />
Airport and only 15 minutes from Perth’s CBD<br />
For more and for registration details see WAVE’s<br />
ad on p15. ▀<br />
School of Optometry graduation celebration<br />
The class of 2015 at the University of<br />
Auckland’s School of Optometry and Vision<br />
Science officially celebrated their graduation<br />
in May with a breakfast for the Bachelor of<br />
Optometry students, before joining the main<br />
graduation ceremony.<br />
Other notable graduates included Associate<br />
Professor Bruce Hadden, who received an MD by<br />
research (see full story p17) and Drs Carol Greene<br />
and Elissa McDonald for completing their PhDs. ▀<br />
PhD graduates Drs Carol Greene and Elissa McDonald<br />
Graduation day for the class of 2015<br />
18 NEW ZEALAND OPTICS <strong>Jun</strong>e <strong>2016</strong>
Around and about at ARVO<br />
NZOSS update<br />
BY JIE ZHANG*<br />
I<br />
was excited to be part of a group of 19<br />
researchers from the New Zealand National<br />
Eye Centre who travelled to the US for the<br />
annual meeting of the Association for Research<br />
in Vision and Ophthalmology (ARVO) at the start<br />
of May.<br />
ARVO, based in the US, is the largest<br />
association in the world for eye and vision<br />
research and their annual meeting is the<br />
place where top researchers gather to present<br />
and discuss the latest treatments, cures, and<br />
preventative measures, years before they<br />
become available. This year’s meeting, held in<br />
the Washington State Convention Centre in<br />
Seattle from 1 to 5 May, attracted approximately<br />
11,000 attendees from about 75 countries.<br />
About 45% of the attendees were from outside<br />
the States.<br />
I’d been invited to give a talk at the Aqueous<br />
humour dynamics session, one of the first of the<br />
five days. With an audience of approximately<br />
100 people it was a bit nerve wrecking at first,<br />
but I felt calm as the session coordinators<br />
introduced my topic. I was asked some<br />
reasonable questions, and the crowd at the<br />
session were generally very friendly.<br />
Other University of Auckland presenters<br />
included Professors Colin Green and Paul<br />
Donaldson, Drs Julie Lim and Hannah Kersten<br />
and Peter Qiu.<br />
Professor Green gave a very interesting talk<br />
at the Cell biology of gap junctions in the<br />
eye mini-symposium about Connexin 43 in<br />
corneal and retinal injury and disease. Professor<br />
Donaldson, Dr Lim and Mr Qiu presented their<br />
research in the Lens physiology and homeostasis<br />
session, and Dr Kersten presented in the Ocular<br />
surface neovascularization, Innervation, and<br />
Immunology session. There were on average 70<br />
paper and poster sessions and symposiums on<br />
any one day, with something exciting bound to<br />
be happening at any given time. This meant I<br />
had to make some really difficult decisions at<br />
times about which sessions to attend.<br />
The good part about speaking so early in the<br />
conference programme was feeling free to relax<br />
and enjoy the rest of the line-up. A highlight<br />
of ARVO is the multitude of guests who chose<br />
to present their work in one of the highly<br />
interactive poster sessions. There is also an “all<br />
poster” session every day to give the audience<br />
another chance to see the posters and talk to the<br />
presenters. These sessions are also well-known<br />
for their high attendance rates due to rules<br />
enforced by conference organisers. If you did not<br />
stand by your poster at the designated time, you<br />
would be banned from submitting an abstract<br />
for ARVO the next year! Poster presenters<br />
typically have between 20 and 30 visitors during<br />
a two-hour poster session, giving them plenty of<br />
chances to discuss their research and network.<br />
One highlight of the scientific programme was<br />
the release of the five-year CATT (comparison of<br />
age-related macular degeneration treatments<br />
The Space Needle observation tower<br />
trial) results, which found increasingly larger<br />
areas of geographic atrophy in patients treated<br />
for two years with ranibizumab or bevacizumab.<br />
The paper’s title is Size and Growth of<br />
Geographic Atrophy During 5 Years of Follow<br />
Up in the Comparison of Age-related Macular<br />
Degeneration Treatments Trials (CATT).<br />
Professor Shigeru Kinoshita, a pioneer in<br />
corneal wound healing and ocular surface<br />
reconstruction, received the Friedenwald Award<br />
from ARVO and gave an inspiring lecture entitled<br />
Medical Science and Future Realities in Corneal<br />
Regenerative Medicine. In this lecture, he<br />
described the safety issues they had to solve in<br />
order to translate cultured corneal endothelial<br />
cells for the treatment of corneal endothelial<br />
diseases into the clinic, which entered clinical<br />
trials in 2013 and is already showing promising<br />
results.<br />
Professor May Griffith gave an update on the<br />
development of a recombinant collagen scaffold<br />
for corneal repair. The originally non-suturable<br />
scaffold has now been reinforced with MPC<br />
for mechanical strength and suturability, and<br />
has been implanted in 10 high-risk patients in<br />
Ukraine with painful ulcerated corneal surfaces.<br />
Dr Jie Zhang, Professor Colin Green and Salim Ismail on a ferry<br />
to Bainbridge Island<br />
I look forward to hearing about the results<br />
in the coming years.<br />
And, of course, <strong>2016</strong> is the year of CRISPR<br />
– Cas9: a gene editing tool to cure diseases.<br />
Gene therapy for eye diseases was a major<br />
focus of the meeting, with one whole day<br />
education course, one symposium, one<br />
special lecture, and numerous posters<br />
dedicated to the topic.<br />
The sight-threatening consequences of<br />
recent viruses such as Ebola, Zika and West<br />
Nile also received the spotlight. A special<br />
session was dedicated to these emerging<br />
systemic infectious diseases, which<br />
reminded the ophthalmology community<br />
of the importance of contributing to an<br />
understanding of disease mechanism<br />
and treatment, and an urgent need for<br />
improved ophthalmic screening and care.<br />
With 12 to 15 concurrent sessions at any<br />
one time, we were all too busy to meet<br />
up during the event. Luckily we managed<br />
to have dinner at the Cheesecake Factory<br />
restaurant and enjoyed it very much!<br />
See you next year at ARVO in Baltimore! ▀<br />
* Jie Zhang is a research fellow in the Department of<br />
Ophthalmology at the University of Auckland. Zhang<br />
is using her biomedical science background to devise<br />
treatments for ophthalmic conditions and is currently<br />
focusing on the synthesis and testing of a novel<br />
collagen based scaffold for corneal transplantation.<br />
BY NIKKU SINGH, NZOSS PRESIDENT<br />
With the second half of semester one in full<br />
swing, it’s a struggle to comprehend where<br />
the past three months have gone! The<br />
younger years have settled in well within the school,<br />
whereas the Part 5’s are becoming more unsettled with<br />
the prospect of being let loose on the real world.<br />
Taking a look back, we kicked off this year with a<br />
week of orientation, initiation and degustation in<br />
the form of our annual New Zealand Optometry<br />
Student Society (NZOSS) BBQ. The great weather was<br />
accompanied by a massive turn out and the existing<br />
student body was able to warmly welcome the freshfaced<br />
Part 2’s. Time was spent reminiscing over our<br />
summer holidays and discussing the week that had<br />
just been. For the Part 5’s, this meant deconstructing<br />
our first taste of back-to-back patients—there’s<br />
nothing quite like a couple sausages to combat the<br />
‘first week of school’ blues.<br />
Round the Bays happened to be scheduled just<br />
two days after the BBQ, proving that a few cheeky<br />
sausages do not constitute an appropriate ‘carbo-load’.<br />
Nevertheless, we carried on in full force eager to pound<br />
the pavement. This year we also had the opportunity<br />
to work with the Fred Hollows Foundation and run for<br />
a great cause, restoring sight to the needlessly blind. It<br />
was a privilege meeting the team driving this fantastic<br />
charity. After the run we were treated to a big feed by<br />
Team Fred, bringing the tally to two BBQs in the space<br />
of a week. We were living the dream!<br />
The next few weeks carried on with our usual student<br />
shenanigans, the annual pub crawl providing a much<br />
needed release of steam following a hectic period of<br />
assessments for all. We finished off term one with our<br />
annual NZOSS Camp. The weekend away was a great<br />
way to usher in the mid-semester break (for those lucky<br />
enough to have one) and was filled with what I can only<br />
call some quality team-building exercises!<br />
<strong>2016</strong> has been a very successful year thus far,<br />
made possible through the hard work of the NZOSS<br />
committee. Of course, the events wouldn’t be what<br />
they were without the co-operation and collaboration<br />
of all the students involved. However, we’ve got plenty<br />
more work to do, with seminars and educational<br />
evenings in the pipeline. Of course, we will slip in some<br />
time for some much needed social soirees, the annual<br />
Eye Ball being the most anticipated event to come.<br />
Lastly, on behalf of the School of Optometry, I would<br />
like to thank all the sponsors for their continuing work<br />
with NZOSS. Not only does it provide us exposure<br />
to the optometry profession, but it also helps in the<br />
development of us as future clinicians.<br />
For those who are interested in collaborating with<br />
NZOSS, please do not hesitate to contact us as we<br />
are always looking for ways to further develop our<br />
connections with the eye care industry. Our email<br />
address is nzoss.uoa@gmail.com. ▀<br />
For more personalised eye care<br />
talk to Dr Hussain Patel<br />
Consultant Ophthalmologist<br />
MBChB, MD, FRANZCO<br />
SERVICES INCLUDE:<br />
Glaucoma Specialist / Refractive Cataract Surgery<br />
General Ophthalmology / Acute & Emergency Eye Care<br />
Available throughout Auckland<br />
and also in Hamilton<br />
Phone 09 486 4372 or Fax 09 486 3936<br />
info@eyesurgeryassociates.co.nz or<br />
Dr Patel at: patel@glaucoma.co.nz<br />
www.eyesurgeryassociates.co.nz<br />
Eye Surgery Associates are a Southern Cross Health Society Affiliated Provider<br />
Dr Jie Zhang, Peter Qiu and Professor Paul Donaldson<br />
<strong>Jun</strong>e <strong>2016</strong><br />
NEW ZEALAND OPTICS<br />
19
We need a gifted Captain<br />
To see us safe and sound<br />
Our crew is close to mutiny<br />
And stormy seas abound!<br />
Well ... not quite! But we do need to commission a store manager<br />
with optical experience to join our jolly crew at Specsavers,<br />
Pukekohe, Auckland, NZ.<br />
* Management experience Please apply in writing to:<br />
preferred<br />
Carleton Buckley<br />
* Uniform provided seebea@gmail.com<br />
* Naval experience not PO Box 127, Pukekohe,<br />
essential! Auckland, 2120<br />
NEED TO REPLACE<br />
YOUR LETTER CHART?<br />
AcuityKit has a comprehensive range of digital eyecharts for eyecare<br />
professionals. Ideal for low vision and domiciliary work.<br />
Visit our website www.acuitykit.com or email john@acuitykit.com<br />
With growth continuing, our store teams are<br />
currently seeking optometrists to fill permanent<br />
roles in the following NZ practice locations:<br />
NZ AND AUSTRALIAN<br />
OPPORTUNITIES!<br />
North Island:<br />
• Auckland CBD<br />
• Botany<br />
• Kerikeri<br />
• Masterton<br />
• Mt Maunganui<br />
• Palmerston North<br />
• Paraparaumu<br />
• Rotorua<br />
• St Lukes<br />
• Taupo<br />
• Tauranga<br />
• Te Rapa<br />
• Wanganui<br />
• Wellington<br />
CBD South<br />
• Whangaparaoa<br />
South Island:<br />
• Dunedin • Invercargill • Shirley<br />
We are currently also seeking experienced<br />
dispensers for a variety of our New Zealand stores.<br />
Alternatively, if you’re interested in a move to<br />
Australia - either short or longer term, talk to us<br />
for the lowdown on possible locations in all states.<br />
To find out more and to explore the Terms and Conditions associated<br />
with this industry-wide offer, contact Carly Parkinson on 0800 717 350<br />
or carly.parkinson@specsavers.com – or visit spectrum-blog.com<br />
OPTICAL ASSISTANT REQUIRED<br />
Here's a chance to work in a great optometry practice in<br />
Newmarket. We are looking for an amazing, passionate, optical<br />
assistant for a full-time role with a potential career path. You need<br />
to be efficient, totally customer focussed, well presented, able to<br />
multi-task and absolutely love beautiful eyewear. If you reckon<br />
you've got what it takes to work in our busy practice please email<br />
your CV to jeremy@gateseyewear.co.nz<br />
NEED A LOCUM?<br />
Call Bharat Raniga, locum optometrist, on<br />
021 424 253 or email: bharatranlga@yahoo.com<br />
AND REMEMBER, UNTIL THE END OF JUNE<br />
<strong>2016</strong>, ANY OPTOMETRIST REFERRALS<br />
YOU MAKE COULD EARN YOU UP TO<br />
$50,000 FOR EACH REFERRAL – SIMPLY<br />
CALL CARLY TO FIND OUT MORE!<br />
ADVANCED SHOPFITTERS ON O/E<br />
Tony Maddocks of Advanced Shopfitters is taking a well-earned<br />
break, travelling around Britain and Europe for the next 12<br />
months. NZ Optics wishes him and his wife Lynette, happy and<br />
safe travels and thanks them for their continued support of the<br />
magazine for more than 20 years.<br />
Whether you are looking for new staff, to sell your practice or buy<br />
some equipment, NZ Optics classified page connects you.<br />
For all your advertising needs email<br />
Lesley@nzoptics.co.nz or<br />
(for classifieds only) do it online at<br />
www.nzoptics.co.nz<br />
PART-TIME DISPENSING OPTICIAN /<br />
OPTICAL ASSISTANT, TAKAPUNA<br />
We are looking for a dispensing optician/optical assistant to<br />
join our independent, high-end optometry practice in Takapuna,<br />
by the beach. The position is for 50-60 hours per fortnight –<br />
including alternate Saturdays and Mondays.<br />
The successful applicant will:<br />
- Be a qualified Dispensing Optician or Optical Assistant with<br />
dispensing experience.<br />
- Display exceptional customer service and sales skills.<br />
- Have a passion for fashion eyewear and leading edge lens<br />
technology.<br />
- Have some social media skills – e.g. Facebook, online customer<br />
communications.<br />
- Have flexibility to provide leave cover for our full-time<br />
Dispensing Optician.<br />
- Be a good team player.<br />
If this sounds like you, please email your CV to<br />
david@haydons.co.nz<br />
C<br />
M<br />
Y<br />
CM<br />
MY<br />
CY<br />
MY<br />
K<br />
Thinking of selling your practice - we have buyers<br />
Considering buying - we’ll give you all the options<br />
OpticsNZ specialises in optometry practice sales,<br />
we've helped dozens of Optometrists buy and sell their practices<br />
For more information contact Stuart Allan on: 03 546 6996<br />
20 NEW ZEALAND OPTICS <strong>Jun</strong>e <strong>2016</strong><br />
027 436 9091 stu@opticsnz.co.nz www.opticsnz.co.nz<br />
<strong>Jun</strong>e Classifieds FINAL<br />
• Locum Service<br />
• Recruitment Services<br />
• Practice Brokering<br />
• Business Consultants<br />
NEW ZEALAND<br />
1